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 Maintaining health and eliminating diseases are always intriguing topics that 
everyone cares about. Along with medical biology and physiology which cover 
knowledge of human tissues and biochemistry, the study of human genomes now also 
attracts our attention.  Gene mutations can cause diseases, exemplified by mutations in 
the genes BRCA1 and BRCA2 which increase a woman’s risk of breast cancer.  However, 
most disease has a more complex genetic basis that is just beginning to be 
explained.  The completion of the Human Genome Project has led to the development of 
genotyping and sequencing techniques in the past two decades that now allow human 
geneticists to better understand the relationship between genotypes and disease. 
            Discovery of associations between genetic variants and disease status or 
quantitative traits is shedding light on disease mechanisms and promoting improved 
prediction of risk.  For many years the prevalent model of disease risk has been the 
“common disease, common variants” hypothesis. It postulates that common diseases are 
mostly caused by common variants of quite large effect. However, the introduction of 
Genome Wide Association Studies (GWAS) in the mid 2000’s has shown that such large 
effect common variants only explain a small proportion of heritability, leading to the 
“missing heritability” problem. Attention has switched to deep DNA sequencing studies 
of rare variants that may contribute to individual cases. However, exome sequencing has 
dominated and the focus has been on rare coding variants.  Rare regulatory variants have 
not been well studied. 
            This dissertation aims at investigating the association between genotypes and 
phenotypes in human. Both common and rare regulatory variants have been studied. The 
phenotypes include disease risk, clinical traits and gene expression levels. This 
dissertation describes three different types of association study. 
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            The first study investigated the relationship between common variants and three 
sub-clinical traits as well as three complex diseases in the Center for Health Discovery 
and Well Being (CHDWB) study. A post test disease probability for the three diseases - 
coronary artery disease (CAD), type 2 diabetes (T2D) and asthma - was calculated 
incorporating prevalence of the disease and the likelihood ratio for all significantly 
associated common SNPs identified by GWAS. The polygenic risk scores for three traits 
– height, body mass index and triglycerides -were calculated based on the total counts of 
alleles which increase the trait levels. Although I studied a small cohort of ~200 people, 
statistically significant relationships were found between polygenic scores and 
quantitative traits, and also between combined likelihood ratio and Framingham risk 
scores for CAD. The explanatory power of the top-ranked SNPs was compared with that 
of all significantly associated SNPs by adding SNPs stepwise to the regression models. 
The result shows that the top-ranked SNPs could explain as much of the variance as is 
explained by the top few hundred SNPs. While the detection of positive genotype-
phenotype associations in a small cohort is encouraging, the results of this study also 
highlighted the limited clinical potential of risk scores based on common variants 
identified in genome-wide association studies. 
            The second study is GWAS analysis of TNF-α and BMI/CRP conducted as a 
contribution to a meta-GWAS analysis of these traits with investigators at the University 
of Groningen in the Netherlands, and the 1000 Genomes Consortium. The TNF-α 
analysis was performed as a replication study, based on 44 SNPs previously discovered, 
but incorporating a linear mixed effect model to account for longitudinal measures 
obtained over three visits. The top-ranked SNPs all replicated despite the small sample 
size of the CHDWB cohort, and the longitudinal model showed essentially the same 
association significance as the baseline-only model.  The GWAS on BMI/CRP was 
performed as a contribution to meta-GWAS discovery analysis after imputing SNPs 
genome-wide. SNPTEST was implemented for the association test with expected and 
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threshold models that provided alternative candidate SNPs for the meta-analysis. This 
study shows that small cohort is nevertheless capable of serving as replication study for 
meta-GWAS analysis. In addition, it confirms that imputation is an effective way to 
detect GWAS signals even with a low resolution genotyping array. 
            The third study was the most original contribution of my thesis as it assessed the 
association between rare regulatory variants in promoter regions and gene expression 
levels. By targeted sequencing of the promoter regions of 480 genes in 410 individuals, I 
was able to develop a novel burden test for rare variants at the extreme of 
expression.  Burden tests were performed by calculating the summed rare allele counts in 
ranked expression level bins for all individuals, and separately for European-ancestry 
individuals for more targeted analyses avoiding possible influences of population 
structure. The results clearly show an enrichment of rare variants at both extremes of 
gene expression. The rare regulatory variant effects were also partitioned into subsets of 
genes based on their regulatory functions, positions relative to transcription start sites, 
disease relatedness, with some intriguing biases. The enrichment of rare regulatory 
variants in extremely expressed genes was replicated using another cohort and different 
sequencing and gene expression profiling technologies. The effects of three of four rare 
variants with large effect sizes were experimentally validated by CRISPR/Cas9 mediated 
genome editing. 
            This dissertation provides insight into how common and rare variants associate 
with broadly-defined quantitative phenotypes. The demonstration that rare regulatory 
variants make a substantial contribution to gene expression variation has important 
implications for personalized medicine as it implies that de novo and other rare alleles 







Description of the Dissertation 
My dissertation aims to investigate the association between genetic variants and 
broadly-defined phenotypes. The broadly-defined phenotypes here include gene 
expression levels, clinical measures and disease risks. The genetic variants include 
common variants and rare regulatory variants. Association analysis is expected to provide 
a better understanding of the genetic contribution to variation of phenotypes among 
individuals, leading to better insight into genetic prediction of diseases.  
 The studies were based on the CHDWB (Center for Health Discovery and Well 
Being) cohort, which is a collaborative center between Emory University, Georgia Tech 
and the ACTSI. The CHDWB cohort includes in total of 697 healthy adults, among 
whom 651 are Emory employees and the remaining small proportion is from the general 
public and Georgia Tech. The individuals had blood withdrawn every six months, with at 
least 3 time points drawn from most of them. The Center provided health partners who 
provided enrolled individuals with health – related advice including exercise, diet 
recommendations intended to maintain or improve their health status. 
 The dissertation is composed of five studies, each with a chapter. The object of 
the first study was to investigate how well common variants explain three quantitative 
phenotypes and 3 common disease risks (Chapter 2) in the small cohort. The quantitative 
phenotypes were height, body mass index and triglyceride; the 3 common diseases were 
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coronary artery disease, type 2 diabetes, and asthma. This study was published in 
Genetics Research and the chapter is slightly edited from the version co-written with my 
supervisor, Professor Gibson. In Chapter 3, GWAS analysis of TNF-α and BMI/CRP was 
performed by participation in the meta-GWAS analysis led by group at the University of 
Groningen in the Netherlands and the 1000 Genomes group, with imputed genotypes 
from microarray data. 
 The object of the third study was to extract the detailed genotype information 
from targeted sequencing (Chapter 4). The targeted sequencing was designed to discover 
rare variant within 1kb of each side of the transcription start site (TSS) of 472 genes. 
Different variant calling algorithms were compared. Rare variants distributions were then 
compared among different populations, and among subgroups of genes, conditioned on 
their regulatory functions, disease relatedness, and other attributes. 
 The fourth study aimed for the first time to investigate the hypothesis that there is 
enrichment of rare regulatory variants in promoter regions in the context of extreme gene 
expression levels (Chapter 5). Rare variants in coding regions are now being investigated 
as a source of congenital abnormalities. My thesis asks whether rare regulatory variants 
might contribute to aberrant gene expression, which might in turn promote disease. These 
associations were also analyzed within subgroups of genes conditioned on disease 
relatedness and regulatory functions. Parts of Chapter 5 have been co-written with my 
supervisor as we prepare to submit the paper for publication, whereas Chapter 4 reports 




Genetic Variation in Human Genome 
 Genetic variation refers to the difference in DNA sequences among samples or 
between populations. Usually it refers to the differences when comparing the genome of 
one person with a reference genome. Genetic variation is caused by mutation and is 
mainly composed of single nucleotide polymorphism (SNP), copy number variation 
(CNV), insertions and deletions (indels) (Figure 1.1) [1, 2]. SNPs, which are polymorphic 
sites affecting a single nucleotide, are the most commonly occurring type of genetic 
variation. Copy number variation is the variation in the number of copies of longer 
sections of DNA between tens and thousands of kilobases. Indels are most often the 









A series of techniques have been designed in order to detect genetic variation. 
Among those techniques, a commonly used one when I started this thesis was genotyping 
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arrays which were initially designed for SNP detection [3, 4]. The basic principle depends 
on hybridization of fragmented single-stranded DNA to complementary nucleotide 
probes in arrays. Each array contains hundreds of thousands of unique probes. After 
hybridization, the signal intensity of fluorescence at each probe is measured. The raw 
signal intensity is then converted to genotypes via computational algorithms provided by 
the manufacturer, in our case Illumina. These SNP arrays have been widely used by many 
project groups such as HapMap consortium. However, SNP arrays have the drawback 
that there is ascertainment bias due to the non-random distribution of SNP probes 
throughout the genome.  
 Starting around 5 years ago, there was a major shift in variant detection with the 
arrival of next generation sequencing (NGS) methods [5, 6]. Compared with automated 
Sanger sequencing [7] which is considered to be a first generation technology, next 
generation sequencing has revolutionized human genetic analysis. It includes DNA 
sequencing [8, 9], RNA sequencing [10, 11], ChIP-sequencing [12] and others, enabling 
the assessment of a broad range of biological phenomena such as genetic variation, RNA 
expression, chromatin conformation, and DNA-protein interactions. The NGS 
technologies differ from the Sanger method in aspects of massively parallel analysis, high 
throughput, and have reduced cost. With the maturation of sequencing technologies, even 
more sequencings reads can be produced within a shorter time and with much lower 
costs. 
 For my research I have used the Illumina Truseq System protocol [13] on Hiseq 
platform. This is a versatile technology that now dominates the market and has well 
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validated performance with relatively low cost. Typically tens of millions of paired reads 
each 100 nucleotides long are generated from either end of DNA fragments. These are 
then computationally aligned to the reference genome to detect sequence variants. The 
process is called re-sequencing since each individual’s DNA is compared with a 
previously known standard, hg19. 
Bioinformatics Tools for Sequencing Analysis 
 Raw sequencing reads require bioinformatics analysis before they can reveal 
scientific insight. From alignment to variant calling to functional annotation, there are 
many types of analysis tools and software. The most popular sequence aligners are 
Bowtie, Bowtie2 and BWA. Bowtie is a short read aligner based on indexes built with the 
Burrows-Wheeler algorithm [14]. Bowtie 2 uses an FM Index (based on the Burrows-
Wheeler Transform (BWT)) to index the genome [15]. Compared to Bowtie 1, Bowtie 2 
performs faster when aligning reads longer than 50bp and deals more flexibly with 
paired-end alignment. The BWA (Burrows-Wheeler Aligner) is based on backward search 
with the BWT [16]. There are also a number of open source variant calling tools 
available. GATK [17] calls SNPs and indels using Bayesian model with Java code. 
GATK applies machine learning methods to base quality recalibration and variant quality 
recalibration. SAMtools [18] uses HMM & MAQ model with C code. It calls the variants 
that maximize the posterior probability with the highest Phred quality score using a 
general Bayesian framework. There are also several other commonly used variant calling 
tools such as VarScan [19] and SNVer [20]. Varscan  is compatible with several aligners 
like Bowtie and BLAT [21] and can process SAMtools pileup files. VarScan calls variants 
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according to the coverage, quality, as well as the number of supporting reads. In my rare 
variant association study, I used BWA to align my targeted sequence data, and chose 
GATK to perform variant calling after comparing different calling methods. 
Genome Wide Association Studies 
Understanding the genetic basis of diseases helps scientists understand the cause 
of disease, predict disease risk in individuals and develop clinical interventions. Prior to 
2007, most research on mapping genetic loci that have effects on diseases or other 
complex traits was performed by linkage analysis [22, 23]. Linkage analysis is based on 
the co-segregation of causal variants with disease status within pedigrees. It has been 
most successfully applied in discovery of genetic variants which are related to Mendelian 
diseases and traits [24]. Since the development of genotyping techniques, especially the 
development of the HapMap project [25], genome-wide association studies (GWAS) have 
been more popular. These are based on the existence of linkage disequilibrium between 
causal SNPs and tagged SNPs in unrelated individuals. Following theory first proposed 
by Risch and Marikengas [26], in 2005, the first GWAS reported two SNPs found to be 
associated with age-related macular degeneration [27]. Since then, GWAS has been 
widely used to find thousands of disease- and trait- associated genetic variants for 
hundreds of clinical phenotypes.  
 At the early stage, GWAS was focused on common variants, based on expectation 
of the common disease - common variant hypothesis [28, 29]. However, it has been found 
that only a small proportion of variance can be explained by common variants, leading to 
discussion of “missing heritability” problem [30, 31]. Much more variance was expected 
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to be discovered, but we now think that most of it is hidden, rather than missing. This is 
because effects of individual SNPs are very small and there is not enough statistical 
power unless hundreds of thousands of people are studied. Subsequently, the hypothesis 
was proposed that rare variants with moderate to high effect size may also contribute to 
the missing heritability. Evidence that rare variants associate with complex diseases and 
traits has been found for schizophrenia [32], HDL [33] and T1D [34]. The frequency and 










Genetic Risk Prediction 
 People care about their health and wellness on a day to day basis. Knowing their 
disease risk may help them to make relevant adjustments to lifestyle, and take precaution 
against diseases enabling them to maintain wellness.  Knowing the classification of high 
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or low disease risk could help people adjust for their lifestyles including eating and 
exercise habits to maintain wellbeing. Disease risk prediction previously was based 
merely on clinical measures such as body mass index, smoking status, lipid levels, and so 
on. With the advent of GWAS, genetic variants have been found to be associated with the 
disease onset and disease status. Incorporating genetic information with clinical measures 
and family history may provide a more informative prediction of the disease risk. While 
most genetic risk prediction is focused on cancers, here I presented a genetic risk 
prediction for 3 quantitative phenotypes height, triglyceride, body mass index, and 3 
common diseases coronary artery disease, type 2 diabetes and asthma, and compared the 
variance explained by genetic information for phenotypes and clinical risk for those 3 
common diseases. However, I concluded that the technology is not yet ready for clinical 
evaluation since too little variance is explained by known SNPs from GWAS. This may 
change in the next 10 years. 
eQTL Analysis 
Gene expression, alongside protein function, is the major source of variation in 
cellular function. The patterns and properties of gene expression influence protein 
activity levels, which then determine cell states. Gene expression also plays an important 
role in disease status by influencing the phenotype. For example, researchers have found 
that the aberrant expression of surfactant protein C may lead to lung disease [36]. As a 
result, gene expression has been attracting scientists’ interest as an intermediate 
phenotype between genetic variants and phenotypic traits. Mutations in the coding region 
may lead to abnormally translated proteins, thus causing change of signaling pathways or 
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other biological processes that the proteins participate in. Abnormally expressed genes 
due to mutations in non-coding regions that for example change affinity of transcription 
factor binding sites, may lead to abnormal genetic regulation and gene expression. 
Therefore, finding the genetic variants that are associated with gene expression levels, 
i.e., expression quantitative trait loci (eQTL), can help reveal the mechanisms of how 
genetic variants influence phenotypes and uncover the genetic basis of many complex 
traits at the molecular level. Recent studies have revealed that there are substantial 
overlaps between eQTLs and genetic variants identified in genome-wide association 
studies which are associated with diseases [37, 38]. It has been shown that trait-
associated QTLs are more likely to be associated with expression levels (Figure 1.3) [38]. 
Therefore, researching the genetic basis for variation in gene expression is not only of 







Figure 1.3 The distribution of the number of eQTLs defined with p-value<10-6 
observed for each of 1000 draws of random 1,598 SNPs (bar graphs), with the actual 
number of eQTLs observed in the 1,598 SNPs from the NHGRI GWAS catalog 




Rare Variant Association Analysis 
 Although the improvement of experimental strategies and statistical analysis have 
enlarged the proportion of gene expression variation explained by common variants, the 
vast majority of gene expression variation still needs to be accounted for. Much of this 
variation is likely due to factors not located within the gene that encodes the transcript. 
This can be trans-eQTL (compared with cis-eQTL, located in the gene itself), systemic 
influences like hormones and metabolites, and the environment. There is also the 
potential importance of rare variants contributing to the regulation of gene expression 
levels. Compared to the rare coding variants whose genetic functions have been studied 
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extensively [39-41], rare regulatory variants have not been systematically studied for 
their effects on gene expression regulation.  
 I assume that the rare regulatory variants affect gene expression is based on the 
following reasons. First, it is possible that a common variant association is actually 
attributed to linkage with multiple rare or less common variants which contribute to the 
major effects, a situation known as synthetic association [42]. A well characterized 
example is the Hepatitis C virus-anemia associated locus ITPA, where the minor allele 
frequency of the causal SNP is much lower than the most significantly associated one 
[43]. Second, analogous to the well known fact that rare variants in coding regions affect 
lipid levels (for example, rare NPC1L1 variants affect plasma LDL lipoprotein levels 
[44]) and gene expression levels (for example, a rare synonymous CRP2 variant affects 
serum CRP level [45]), rare polymorphisms in regulatory regions could also influence 
differential transcript abundance, by affecting the regulatory effects of transcription of the 
nearby gene. Promoter regions, which play an important role in regulating the 
transcription process, are an ideal choice for initial regulatory rare variant studies, since 
enhancers vary greatly in their complexity and location relative to TSS. Third, my 
hypothesis is that the observed enrichment of common eSNPs in promoter regions 
(Figure 1.4) [46], may also imply that rare variants in promoter regions also are likely to 
affect transcription. Recent work such as ENCODE project [47, 48] has established the 
complexity of regulatory regions, leading to the expectation that more than one causal 







Figure 1.4 The probability of a random SNP (or the SNP conditioned on different 




In standard GWAS, individual variant tests are employed to test common variant 
association. However, considering the small individual effect size and the low allele 
frequency of rare variants, single variant tests will be underpowered to detect rare variant 
effects. In consideration of this, collapsing the rare variants in a region is the most 
commonly used approach for analyzing rare variant association. Among the region-based 
rare variant tests, the most popular ones include burden tests such as the cohort allelic 
sum test (CAST) [49], the combined multivariate and collapsing (CMC) method [50], and 
the weighted sum rare allele rank test (WSRRT) [51]. CAST compares the number of 
individuals with at least one rare variant between affected cases and unaffected controls. 
CMC collapses all the rare variants as a common variant and performs a multivariate 
regression together with other common variants. WSRRT weights the rare variant score 
by the rare allele frequency among unaffected individuals, add ups the ranks of 
individuals based on the weighted score, then performs a permutation to compare the 
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rank sum difference between affected and unaffected groups. There are some other rare 
variant association tests not based on the simple total burden, which take the possible 
different directions of effect into consideration. This is important for regulation of 
transcription, since rare variants might either increase or decrease the activity of the 
promoter. Among these tests are the well-known C-alpha test [52] and Sequence Kernel 
Association Test (SKAT) [53]. The C-alpha test contrasts the expected variance with the 
actual variance of allele frequency distributions, testing for a mixture of effects across a 
set of rare variants. SKAT is a regression based approach which tests for association of 
rare (and common) variants with a dichotomous or continuous phenotype while adjusting 
for covariates.  
However, these tests require sample sizes of at least tens of thousands of 
individuals, and we do not have gene expression datasets that large.  Consequently I 
proposed a pooling strategy, which required the development of a novel test based on the 
significance of the quadratic component of a regression of rare allele burden on rank of 
expression.  This is described in Chapter 5 and shown to provide strong and replicated 





GENETIC RISK PREDICTION 
 
Introduction 
Despite high heritability, most complex traits and diseases in humans have such a 
polygenic inheritance pattern that prediction of phenotype or liability on the basis of 
genetic risk profile has proven elusive. The possible benefits of genetic risk evaluation 
were recognized more than a decade ago [54-56], but only recently has the application of 
high-density genotyping technology [57] brought us closer to the goal. Polygenic scores, 
which represent the summed effects of multiple trait-associated genetic variants, contain 
more information than single markers and explain more of the variance in phenotype or 
disease risk. This type of analysis has been applied to several complex traits including 
height [58], body mass index [59], and rheumatoid arthritis [60], in each case evaluating 
the joint effects of polymorphisms identified in samples of tens or even hundreds of 
thousands of individuals, in large validation cohorts of several thousand. 
Most cohort studies are focused on a single trait or condition, so do not allow the 
evaluation of genetic risk across multiple phenotypes. Here I report on common variant 
contributions to three traits and three diseases in the Emory-Georgia Tech Center for 
Health Discovery and Wellbeing study of clinically deeply profiled adults, 182 of whom 
have SNP array genotype information available.  Despite the relatively small size of the 
cohort, I nevertheless detect significant association with quantitative traits, and take the 
opportunity to compare methods that do or do not weight allelic effects, while also 
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comparing genetic risk scores with Framingham risk scores for coronary artery disease 
and type 2 diabetes. Examination of the correlations highlights the strong influence of 
outliers on risk prediction, and raises the hope that in a well-characterized cohort it may 
be possible to identify the hidden variables that are shared by such outliers, which may in 
turn suggest strategies for conditional analysis to uncover more of the hidden heritability. 
Some studies have also reported that most of the variation explained by polygenic 
risk scores can actually be explained by the top-ranked markers [61, 62]. The rationale is 
that the top-ranked markers tend to have the largest genetic effects, so explain more of 
the disease or trait than markers that only emerge once large-scale meta-analyses have 
been performed. The proportion of variance that they explain will be a function of the 
distribution of effect sizes, which is itself difficult to estimate due to the high noise level 
in GWAS data. Therefore, the risk attributable to top-ranked SNPs is an empirical 
question, and my dataset allowed me to address performance across phenotypes in the 
same individuals. I applied forward-step regression adding alleles sequentially to 
investigate the influence of adding more marker information to the regression on 
explaining the genetic variance. It turns out that in the small cohort of 182 people 
considered in this Chapter, the inclusion of covariates such as gender and ethnicity, 
influences performance of genetic risk scores, presumably because of residual correlation 
between genotype and those covariates. While the detection of positive genotype-
phenotype associations in a small study is encouraging, the results also highlight the 
limited clinical potential of risk scores based on common variants identified in genome-
wide association studies [63].  
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Materials and Methods 
Participants 
The CHDWB is a longitudinal study of health measures in over 600 employees of 
Emory University.  I describe data for 182 participants for whom genotypic data was 
available, consisting of 136 Caucasians, 34 Africans, 11 Asians and 1 American Indian. 
Two thirds of the individuals were women (120 females and 62 males), and the ages 
ranged from 26 to 79. The data of interest for this study is height (in cm), BMI (weight 
/height2 in kg/m2), serum triglyceride levels (mg/dL), serum cholesterol levels (mg/dL), 
and various measures of blood flow and arterial stiffness.  I also computed Framingham 
risk scores for type 2 diabetes and for coronary artery disease as described in [64, 65]. 
Genotypes 
Whole genome genotypes were measured using Illumina OmniQuad arrays which 
contains 733,202 probes. Identities of 169 Height, 49 BMI, 48 triglyceride, 34 coronary 
artery disease, 66 type 2 diabetes, and 31 asthma related SNPs were collected from the 
dbGaP database hosted by the US NIH, in March 2012. All of the selected SNPs were 
previously reported to be significantly associated with the respective traits or diseases at 
the significance level of p < 10-7. Individual genotypes for each of these SNPs were 
extracted, or if missing from the Illumina genotype data files, were imputed using 
IMPUTE2 [66].  Accuracy of the imputation was estimated to be 98% by comparison 
with 9 individual whole genome sequences (2 African Americans, 7 Caucasians). 
Genetic Risk Score Analyses 
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Three approaches to calculating the proportion of phenotypic variance explained 
by the common genetic variants were considered. All computations were performed using 
R scripts. For the continuous quantitative traits height, BMI and triglyceride level, I first 
calculated the sum of increasing alleles for each individual. Second, I calculated a 
weighted sum of allelic effects according to the effect size of each SNP reported in 
dbGaP. Each of these allelic sum and weighted allelic effect scores was then linearly 
regressed on the relevant phenotype(s), with or without adjustment for gender and 
ethnicity. In the latter case, the genotypic contribution was estimated from the difference 
in the variance explained (R-squared on the Pearson correlation coefficient) by the 
models including the genetic risk (allelic sum, or weighted allelic effect) score, and 
without it. Furthermore, the influences of gender and ethnicity were estimated directly 
from our cohort by including these terms as covariates; or by incorporating reported 
population averages for each gender and ethnicity from the CDC website as “pre-height”. 
For disease risk variants, the third approach was to compute the multiallelic odds 
ratio essentially as described in Ashley et al.[67]. I computed an adjusted relative genetic 
risk by setting each individual’s prior odds as that corresponding to the prevalence for 
their gender and ethnicity as reported by the CDC. In order to obtain the genetic 
contribution to the post-test odds, a slight adjustment to the Ashley et al. [67] method was 
performed as follows.  According to those authors,  
pre-test odds = pre-test probability/(1-pre-test probability);  
post-test odds = pre-test odds×LR;  
post-test probability = post-test odds/(1+post-test odds).  
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Rearranging their equations,  
post-test probability = pre-test probability×LR/(1+pre-test probability×(LR-1)).  
As the reported 95% confidence intervals for genotypic contribution LRs lie between 1.6 
and 0.7, pre-test probabilities range between 4.2% and 14.3%, then post-test probabilities 
range from (0.93~1.04)×pre-test probability×LR. It follows that I can approximate the 
post-test probability as the pre-test probability×LR. That is,  
log10(post-test probability)=log10(pre-test probability)+log10(LR)).  
I confirmed this relationship by observing that this approximated post-test probability is 
highly significantly linearly associated with the post-test probability using Ashley et al’s 
method (P <2×10-16).  The advantage of my portioning is that it allows estimation of the 
genetic contribution to the post-test probability independent of the pre-test probability.  
In order to ask whether addition of more SNPs always improves risk prediction, 
the SNPs were sorted by previously reported effect sizes from larger to smaller. Each 
SNP was added sequentially to the regression model, taking the negative log10 p-value 
and percent variance explained by each successive model. For comparison with random 
SNP selection, I randomly added those SNPs sequentially to the regression model, and 
then averaged the percent of variance explained by each successive model, averaging the 
results over 100 permutations.  
Results 
Regression of Genotypic Risk Scores on Phenotypes 
Significant and positive regression of genotype on phenotype was observed, as 
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expected, for each of the continuous traits (height, BMI, and serum triglycerides) as 
shown in Table 2.1.  In each case, the estimated variance explained by the SNPs was in 
the range of 3% to 5%, which is lower than that reported in the respective discovery 
samples [58, 60, 68]. The inclusion of an estimated effect size in weighted sum scores did 
not significantly improve the model fitting. For each of these traits, gender and ethnicity 
explains considerably more of the variance than the genotypes, and fitting these 
covariates slightly improved the estimate of the genetic contribution (with the exception 
of the weighted sum for BMI). The weighted sum was not calculated for triglycerides 
since the effect sizes were not fully reported in dbGaP. I also fit multiple regression 
models based on jointly fitting all of the SNPs for each trait, and although the variance 
explained reached 16% for height the estimates were not significant after adjustment for 
the number of SNPs included. 
Regressions were also computed for disease-associated risk scores, namely: T2D 
risk with the Framingham T2D risk score, and with serum triglyceride, cholesterol, 
fasting glucose, and insulin levels; CAD risk with the Framingham CAD risk score, 
blood pressure, arterial stiffness, and serum metabolites; and asthma risk with estimated 
VO2-max from treadmill performance. Only two of these analyses (CAD SNPs with 
Framingham CAD risk score, and with cholesterol) yielded nominally significant 
correlations as reported in Table 2.1, and these would not formally survive adjustment for 
multiple comparisons.  Nevertheless, for CAD, the total number of increasing alleles 
showed a surprising positive relationship with total cholesterol levels, even though there 
is little overlap between these SNPs and those associated with cholesterol by GWAS.  
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Table 2.1 Variance explained by genetic risk scores. 
 





          All samples     CAU only     
 Height  Height Allele sum         - 0.027 0.026 2.70% 0.025 0.066 2.50% a 
Height  Height Allele sum Gender/Ethn 0.467 4×10-4 4.00% 0.45 0.002 4.00% 
 Height  Height Weighted sum         - 0.037 0.009 3.70% 0.036 0.027 3.60% b 
Height  Height Weighted sum Gender/Ethn 0.466 5×10-4 3.80% 0.498 0.001 4.20% 
 Height  Height Weighted sum Pre-height 0.027 0.026 2.70% 0.498 0.001 4.20% 
 BMI  BMI Allele sum         - 0.052 0.002 5.20% 0.065 0.003 6.50% c 
BMI  BMI Allele sum Gender/Ethn 0.18 0.001 5.30% 0.087 0.003 6.10% 
 BMI  BMI Weighted sum         - 0.051 0.002 5.10% 0.029 0.049 2.90% d 
BMI  BMI Weighted sum Gender/Ethn 0.169 0.003 4.20% 0.054 0.047 2.90% 
 BMI  BMI Weighted sum Pre-height 0.101 0.005 4.10% 0.054 0.047 2.90% 
 Triglycerides Triglycerides Allele sum         - 0.042 0.005 4.20% 0.067 0.002 6.70% e 
Triglycerides Triglycerides Allele sum Gender/Ethn 0.115 0.003 4.50% 0.115 0.001 7.60% 
 CAD  Cholesterol Allele sum         - 0.044 0.005 4.40% 0.028 0.052 2.80% f 
CAD  Cholesterol Allele sum Gender/Ethn 0.005 0.06 4.30% 0.569 0.04 1.40% 
 CAD  Log10(FHS+1) Log10(LR)         - 0.055 0.02 2.00% 0.053 0.007 5.30% g 
CAD  Log10(FHS+1) Log10(LR) Log10(pre-test) 0.008 0.418 2.30% 0.062 0.006 5.40% 
 CAD  Log10(Chol) Log10(LR)        - 0.015 0.032 3.20% 0.036 0.028 3.60% h 
CAD Log10(Chol) Log10(LR) Log10(pre-test) 0.016 0.042 3.20% 0.046 0.023 3.80%   
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Table 2.1 shows that regression of genotypic risk scores on phenotypes was little 
affected by considering only the Caucasians.  The proportion of variance explained by 
SNPs for triglycerides and CAD was slightly increased relative to the full cohort, likely 
due to better capture of LD between tagging and causal SNPs in Caucasians, but this 
effect is offset by the smaller sample size for other traits.  
Effect of Number of Alleles on Risk Prediction 
 Step forward regression, sequentially adding SNPs in the order of previously 
reported effect size, was performed to address whether the addition of more SNPs to the 
model continuously improves the prediction.  Figure 2.1 shows the results for height, 
BMI, and cholesterol on the left hand panels, compared with average effects for 100 
randomly permuted orders of SNP addition on the right panels. In each case, explanatory 
power of the SNPs increases at least for the first 30 SNPs included in the model. 
 For height (Figure. 2.1 a and b) it is also clear that most of the variance is 
explained by the top 30 SNPs and that sequential addition up to 169 SNPs does not 
improve the fit.  Models without gender and ethnicity covariates (blue and brown curves) 
actually explained the most variance when an intermediate number of SNPs were 
selected. However, since inclusion of more SNPs reduced the estimates to levels more 
consistent with those obtained when gender and ethnicity are included, the scores with 
intermediate numbers of SNPs are likely to be over-estimates.  For BMI (Figure 2.1 c and 
d), there is a suggestion of a plateau effect after 10 SNPs, without a clear further increase 
until 40 SNPs are included in the model. In this case, fitting gender and ethnicity does not 
affect the genetic estimates. For CAD (Figure 2.1 e and f), significant explanation is not 
observed until 30 SNPs are included, but there may be a plateau thereafter, and the 
estimates are not obviously influenced by inclusion of the covariates. For BMI and 
cholesterol, the weighted sum (or likelihood ratio) scores performed slightly less well 




Figure 2.1  The percentage of variance explained by the models with sequentially 
adding SNPs in the order of their effect sizes and compared with random orders. 
The percentage of variance explained by the model by sequentially adding SNPs (Height, 
BMI and cholesterol-CAD SNPs from top to bottom, (a), (c) and (e)). Right: The 
percentage of variance explained by the models randomly adding SNPs (Height, BMI and 
cholesterol-CAD SNPs from top to bottom, (b), (d) and (f)) averaged over 100 
permutations. SA refers to models with just the sum of alleles score, while eg_SA refers 
to models additionally fitting ethnicity and gender as covariates with the sum of alleles 
score. WS refers to models with sum of weighted allelic effects, while eg_WS and 
pre_WS refer to weighted allelic sum includng ethnicity and gender in the CHDWB 
cohort, or taken as the population averages, as covariates respectively. LR refers to 
likelihood ratio models, with or without pre-test probability as a covariate.  
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Effect of Outliers on Explanatory Power 
Inspection of the regression plots in Figure 2.2 suggests the estimated variance 
explained can be strongly influenced by outliers. Thus, the sum of alleles test for height 
in males shows several men who grow taller than their genetic information predicts 
(asterisks in Figure 2.2). Except for one Asian, all of these men are Caucasians. Removal 





Figure 2.2  Linear regression plot fitting real height by sum of increasing alleles in 
males. Red dots Caucasians; blue American Indian; green African Americans; purple 
Asians. Asterisks: the individuals who are taller than their genetic information would 
indicate. Red line: regression fitting line for all men. Green line: regression fitting line for 




The sum of alleles test plot for triglycerides (Figure 2.3) appears to differ between 
higher and lower triglyceride levels. If the analysis is restricted to individuals with TG 
more than 100 mg/dL, the genotypes explain a trivial 0.5% of the variance, while 
regression on the remaining individuals with lower TG has a similar slope but explains 
5.3% of the variance.  The increased phenotypic variance in the high triglyceride range 
reduces the significance of the overall regression even though the slope is greater than in 
either the low or high TG ranges. Moreover, the association is more significant in 
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Figure 2.3  Linear regression plot fitting total triglyceride levels by sum of 
increasing alleles. Dots: TG > 100 mg/ml. Triangles: TG < 100 mg/ml. Red line: linear 
regression for all the individuals (P=0.0053, R2=0.042). Blue line: linear regression for 
individuals with TG > 100 mg/ml (P=0.5453, R2=0.005). Green line: linear regression for 





Figure 2.4  Regression of Framingham risk score for heart against likelihood ratio 
and allelic sum score. (a) Regression of log10(FHS for heart disease) against genotypic 
log likelihood in males.  Exclusion of five older Caucasian males (asterisks) elevates the 
regression from P=0.18, R2=0.03 to P=0.0065, R2=0.13. (b) Logistic regression of 
Framingham risk status on sum of CAD risk alleles in all study participants shows a 
significant association (P=0.0221, R2=0.027). Red dots: Caucasians, blue: American 
Indian, green: African Americans, purple: Asians. Circles females, Triangles males.  
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The regression plot for logarithm transformation of Framingham heart disease risk 
score and likelihood ratio for CAD SNPs in males shows that there are five Caucasian 
males (asterisks in Figure 2.4 a) who have higher Framingham risk scores than expected. 
They are all older than the average male ages. Exclusion of those five males results in a 
more significant association (Figure 2.4 a). In addition, I set Framingham risk status as 0 
and 1 based on the Framingham risk scores (0 when FRS <4, 1 when FRS >=4). The 
logistic regression shows a significant association between Framingham risk status and 
sum of CAD risk alleles (Figure 2.4 b), but the area under the ROC curve is just 0.60, 
indicating that this is not a clinically useful predictor [69]. 
For BMI (Figure 2.5 c), the weighted sum regression plot suggests that the 
genotypes are more strongly associated with the BMI in African Americans than 
Europeans. While weighted sum of effects account for 17% of BMI variation in African 
Americans, the effects only explain 3% of variation in Caucasians. The high variance 
explained in African Americans is plausibly an overestimate due to the small sample.  
Stability of Height Predictions to Number of Included SNPs 
I also re-estimated each person's height predictors (allelic sum score, and 
weighted allelic effect score) from the average of 100 bootstrap samples of 50, 75, and 
100 SNPs. The estimates were all highly correlated (Spearman’s rank correlation 
coefficient ρ>0.99) and explained almost the same percentage of variance for height. 
Similarly, the BMI predictors from the average of 100 bootstrap samples of 30, 40 and 49 
SNPs were also highly correlated and contributed similarly to the BMI variance. This 
suggests the increased estimated variance explained for intermediate number of SNPs in 
height and for more than 40 SNPs in BMI is probably just noise contributing false 
positive signal.  A corollary is that an attempt to include all available SNPs in a model is 
not necessarily guaranteed to yield the most accurate predictor, since, for example, had 
only the top 80 SNPs for height been available, more variance would have been 
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explained than is reasonable given the stepwise increments expected for each additional 
SNP.  On the other hand, the addition of the last 10 SNPs markedly reduced the 
proportion of variance explained using just the allelic sum score for height, suggesting 
more stable predictors might sometimes be obtained by considering a range of numbers 




Figure 2.5 Linear regression between observed traits and predicted traits (or 
predicted disease probabilities). The graphs on the left hand side show the relationship 
between (a) height, (c) BMI and (e) serum triglyceride concentration with sum of 
increasing alleles, while those on the right show the relationships with the weighted sum 
of allelic effects (b) height and (d) BMI. The bottom plots show the regressions with 
CAD risk allele scores, namely between log10(Framingham risk score for heart disease 
+1) and log10(likelihood ratio) (f), between total cholesterol levels and sum of CAD-risk 
alleles (g), and between log10(cholesterol) and log10(likelihood ratio) for the CAD risk 
alleles (h). Circle markers and triangle markers represent females and males. Green 




According to my results, genotypes ascertained for the most part in large GWAS 
metanalyses are somewhat predictive of the relevant traits in our small study cohort of 
typical residents of Atlanta, Georgia.  In general, however, the amount of variance 
explained was smaller than expected, and for CAD and type 2 diabetes the genotypes 
were not significant predictors of individual disease status.  Approximately 4% of height 
variance was explained by the 169 SNPs whether using sum of increasing alleles, or 
using weighted sum of effects. This contrasts with 10.5% of adult height variance (using 
sum of effects method) being explained by 180 SNPs in the analysis of 133,653 
individuals [58].  The 700 fold difference in sample size may contribute to the halving of 
the variance explained, since inspection of the data suggests that a small fraction of 
outliers (taller than expected men) strongly influence the regression.  Additionally, the 
Atlanta cohort is ethnically diverse, and covers three generations that would have 
experienced very different socio-economic conditions during growth.  On the other hand, 
it is surprising that the amount of variance in BMI explained by our 49 SNPs is similar to 
the 4.1% of variance in BMI that is accounted for by 56 variants in a 3,600 sample 
discovery cohort [61].  The heritability of BMI is considerably lower than that of height, 
and gender and ethnic differences are strong, yet the genotypic risk score was more 
consistent than that for height. 
In comparison with the recorded 10% triglyceride variance explained by common 
SNPs [70], the 48 SNPs in my study explained just 4.5% of triglyceride variation. An 
unexpected finding was that approximately 4.3% and 3.2% of the variation of total 
cholesterol levels could be attributed to the 34 CAD-related SNPs, performing sum of 
increasing alleles and multiplication of likelihood ratios respectively.  This is the same 
order of magnitude of explanation as height and BMI, both of which are due to SNPs 
discovered for the respective trait.  The CAD SNPs are related to all forms of coronary 
artery disease, including atherosclerosis, which is certainly related to cholesterol levels, 
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but there is no obvious enrichment in the SNPs for cholesterol metabolism.  
Correspondingly, variation in the Framingham risk score was also partially explained by 
the likelihood ratio score from the CAD-related SNPs, at a level only slightly less than 
the 4% explained in [71].   
Weighting the allelic effects by the effect sizes reported on dbGaP did not notably 
improve the prediction of height, BMI, triglycerides or cholesterol. This is perhaps not 
surprising since there is large variance in the estimation of effect sizes, and to some 
extent including them in the model adds as much noise as it does signal.  In addition, the 
effect sizes recorded in dbGaP were obtained from the studies which are usually 
composed of one specific ethnicity (generally European). Even in a few studies whose 
samples contain more than one ethnicity, the compositions are different from ours. For 
example, Gudbjartsson et al. [72] recorded effect sizes for 35 of our height SNPs in a 
study composed of 25,174 Icelanders, 2,876 Dutch, 1,770 European Americans and 1,148 
African Americans, which is obviously different from the ethnicity composition in our 
study, which has 19% African American and 6% Asian. These differences in ethnicity 
composition could result in the different effect sizes of the SNPs, further reducing the 
accuracy of the weighted allelic effect scores. It is also the case that reduced linkage 
disequilibrium in Africans should decrease the proportion of causal effects captured by 
tagging SNPs, which should reduce the variance explained in the full model. 
The identification of subsets of outlier individuals who do not fit the general 
correlation between genotype and phenotype has implications both for improved 
estimation of individual genetic effects, and also for prediction.  To the extent that shared 
properties of such individuals can be identified, those properties can be considered as 
covariates in statistical models, either as regular environmental effects or sources of 
genotype-by-environment interaction.  This conclusion is at odds with arguments that 
GE is unlikely to contribute strongly to explained genetic variance [73] or prediction 
[74]. I think it is relevant that interactions such as those in Figure 2.2 are between the 
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environmental property shared by the outliers, and the genotypic risk score, rather than 
with single genotypes.  Since the risk score is the sum of 30 or more effects, individual 
genotype-by-environment interactions can be small, and if they only affect a few 
individuals, they will not make a substantive contribution to risk averaged across the 
population. Marigorta and Gibson [75] on our group explored this possibility by 
simulation and confirmed that Genetic Risk Score-by-Environment effects are much 
easier to detect than Genotype-by-Environment effects. 
In predictive health genetics it may be a problem that variants that exceed GWAS 
thresholds only explain a small fraction of the heritability [63, 76], and yet there is 
widespread intention to use these variants to classify individuals with respect to disease 
risk. A possible rationale for this can be seen in the result that most of the genetic signal 
is actually due to the SNPs with the strongest effect sizes. This is clearly the case for 
height, and to some extent triglycerides and cholesterol, though I do not yet have data on 
whether the addition of a further 100 SNPs would improve the BMI prediction. If effect 
sizes are Poisson-distributed, then the contributions of the top 30 SNPs are likely to be 
much greater than those of the next 100 SNPs, which may just tend to cancel one another 
out and contribute noise. Whole genome regression methods show that inclusion of 
undiscovered variants can improve genetic prediction [77, 78], but my results suggest that 
for individually ascertained SNPs, the top few dozen variants will often be as good as the 
top few hundred.  Although they only explain a small fraction of the variance, in keeping 
with individually small effect sizes, it is notable that the effects are significant across 




META-GWAS ANALYSIS ON TNF-α and CRP/BMI 
 
Introduction 
GWAS aims to detect variants in particular single-nucleotide polymorphisms that 
are associated with complex traits such as common diseases and clinical quantitative 
traits. In the last decade, hundreds of diseases and traits were investigated by GWA 
studies and thousands of SNP associations have been found. The number of loci found to 
be associated with diseases and traits continues to expand with the development of 
improved genotyping arrays, methods for imputation, next generation sequencing, and 
advanced statistical methods. 
Tumor necrosis factor alpha (TNF-α) is a key mediator of inflammatory disease 
[79]. It is a cytokine involved in inflammation and acute phase reaction stimulation. 
While it can be produced by many cell types such as CD4+ lymphotypes, NK cells and 
neutrophils etc, it is produced mainly by activated macrophages. TNF-α plays an 
important role in cell signaling by activating NF-ĸB, MAPK, and the apoptosis signaling 
pathway after it binds with TNF receptors. Here I performed a replication study for TNF-
α with 44 lead SNPs as the replication component of a meta-GWAS for TNF-α, in which 
16 cohorts were participating with in total > 23,000 individuals. 
C-reactive protein is also an acute-phase protein [80]. The level of CRP rises in 
response to inflammation and tissue damage. Body mass index, defined as body mass 
divided by the square of height, is one of the commonly used criteria for classification of 
underweight, normal, overweight, and obesity. It is also a useful predictor of health 
status. Many studies have shown that there is an association between CRP levels and 
BMI [81, 82]. In order to evaluate whether the correlation is due to causation or 
independent correlation between two phenotypes and another causal variable, an 
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approach known as Mendelian randomization [83] has been proposed.  The genotypes are 
considered to be the possible alternative variable, and their influence on BMI is evaluated 
with and without CRP in the model. Here, I participated in the GWAS meta-analysis of 
CRP/BMI as a proof of the principle of bidirectional Mendelian randomization model. 
Materials and Methods 
Imputation 
a. Samples 
 The CHDWB cohort was genotyped in three batches.  A total of 156 samples 
were genotyped for batch I, and 144 samples for batch II.   The first step of the TNF-α 
GWAS was to impute 8.5 million SNP genotypes based on the 1000 Genomes project 
data.  Prior to imputation, PLINK QC procedures [84] for genotype data cleaning were 
performed following instructions provided by the consortium to ensure comparison 
across contributing studies. The quality for samples was checked including sex 
concordance between annotation and genotypic implication; missing call rate (MCR, set 
at 0.05 for both batches); sample relatedness; and population structure. After the QC 
process, a cleaned dataset of 153 unique samples for batch I and 144 unique samples for 
batch II was yielded. 
b. SNPs 
All samples in CHDWB were genotyped with Illumina genotyping array. 209 
samples (in phase I) were genotyped using Illumina OminiQuad array which contains 
733,202 SNPs, another 156 and 144 samples (in phase II) were genotyped separately in 
two batches using the Illumina CoreExome array. The genotypes were imputed by using 
IMPUTE2. The phase I data was imputed by UW-Seattle group (Cathie Laurie and Sarah 
Nelson). The phase II batches were imputed by me using the same protocol as with phase 
I. Here I only describe the methods and results for the 2 batches in phase II. 
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 Both batches were genotyped on the Illumina Human CoreExome array. The array 
version of batch I was HumanCoreExome-12v1-0_B, which was based on human 
genome build 37 and contains 542,882 SNPs. The array version of batch II was 
HumanCoreExome-12v1-1_B, which was also based on human genome build 37 but 
contains 542,585 SNPs.  The arrays differ from the OmniQuad array used in Phase I by 
having fewer SNPs overall, but a much higher density of all coding region SNPs 
including most known variants down to a minor allele frequency of 0.01 in 
Europeans.  Consequently, the common intergenic variants are sparse and imputation was 
not expected to be as comprehensive as in Phase 1.  PLINK QC procedures were used to 
identify poor quality or otherwise questionable SNPs. The QC checks in SNP level 
included MCR; Hardy-Weinberg equilibrium; and sex differences according to allelic 
frequency or heterozygosity rate. Table 3.1 shows the number of SNPs lost and SNPs left 
after each filter step. Where an observed study SNP had sporadic missing data, the 




Table 3.1 Summary of SNP quality filters from genotype data cleaning. Top: batch I. 
Bottom: batch II. 
 
Filter SNPs lost SNPs kept 
SNP probes NA 542,882 
missing call rate > 0.05 47,250 495,632 
HWE p-value < E-4 6,335 489,297 
sex difference in allelic frequency >= 0.2 10 489,287 
sex difference in heterozygosity rate > 0.3 0 489,287 
 
Filter SNPs lost SNPs kept 
SNP probes NA 542,585 
missing call rate > 0.05 3,599 538,986 
HWE p-value < E-4 34 538,952 
sex difference in allelic frequency >= 0.2 384 538,568 





c. Data formatting 
 The raw Illumina text files were first re-formatted to long-format fileset (LGEN), 
then converted to PLINK binary file with the samples passing the QC.  
 Before imputation, bed files were made from PLINK binary files for each 
chromosome. The haploid genotypes in chromosome X in male which were called as 
heterozygotes were set as missing. Only the SNPs and samples which have passed the 
QC filtering were included in the output bed files. In addition, the strands of the variants 
were flipped if they were not “+” strands according to Illumina annotation. An example 
of the command line to create the bed files is shown below.  
plink --bfile Coreexome_genotype \  
--extract snp_passquality.txt --flip fliplist.txt \  
--keep sample_keep.txt --set-hh-missing --chr 1 \  
--make-bed -–out Coreexome_chr1 
     d.  Pre-phasing 
 The bed file creation is followed by pre-phasing with SHAPEIT2 haplotype 
estimation tool [85]. SHAPEIT2 could get the best guess haplotypes based on the input 
bed files. Then the best guess haplotypes were used by IMPUTE2 [86] to perform 
imputation. An example of the command line to run pre-phasing is shown below.  
shapeit2 -B Coreexome_chr1 \  
-M genetic_map_chr1_combined_b37.txt \  
-O Coreexome_chr1.haps.gz Coreexome_chr1.sample.gz \  
-S 200 –T 3 -L shapeit_chr1.log 
    e. Reference panel 
 The reference panel data was downloaded from the September 2013 release of 
1000 Genomes on the IMPUTE2 website and the previous March 2012 version was used 
for the X chromosome. As 1000 Genomes sequencing data generally has low coverage 
[87], the variants with very low frequency especially many singletons are likely to be 
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genotyping errors. To avoid imputation errors caused by very low frequency variants, 
imputation was only performed on the variants with at least two copies of the minor allele 
in EUR and AFR samples in 1000 Genomes project. According to the number of samples 
in EUR and AFR group, the filtering cutoff of minor allele frequency of EUR was 0.0026 
and of AFR was 0.004. All three variant types (SNPs, indels, and SVs) were included in 
the imputation. EUR and AFR refer to European and African ancestry individuals. 
f. Imputation 
 An example of the command line to run imputation is shown below. 






-int 0 5000000 -buffer 500 -allow_large_regions \ 
-known_haps_g Coreexome_chr1.haps.gz \ 
-filt_rules_l 'eur.maf<0.0026' 'afr.maf<0.004' \ 
-o Coeexome_imputed_chr1_set1.gprobs -os 0 2 –o_gz\ 
-i Coreexome_imputed_chr1_set1.metrics –verbose 
TNF-α Study 
            TNF-α was measured from buffy coat samples isolated from peripheral blood. 
Buffy coats contain most of the white blood cells and platelets after density gradient 
centrifugation of blood. The unit of TNF-α was pg/ml. There were 266 Caucasians 
(Europeans) in the CHDWB cohort whose TNF-α levels were available. The TNF-α level 
was first transformed to the natural logarithm. Nine samples whose ln(TNF-α) level was 
larger than 4 standard deviation from mean levels were excluded. Therefore, there were 
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257 samples included in the study which were comprised of 98 males and 159 females. 
The age ranged between 19 and 82 with a mean of 50.1 and standard deviation of 10.9. 
            The first visit (baseline) TNF-α ranged from 0.1 pg/ml to 36.2 pg/ml with mean of 
4.1 pg/ml and standard deviation of 3.3. The covariates were sex, age, age2, and BMI. 
BMI has a mean of 26.8 kg/m2 and a standard deviation of 5.0. The first step was to run a 
linear regression on ln(TNF-α) while adjusting for covariates. The regression was 
performed on both sexes combined, and each sex separately. The regression model for 
combined men and women was: ln(TNF-α) = age+age2+BMI+sex. The modes for each 
sex were: ln(TNF-α) = age+age2+BMI. The residuals for each model were saved as the 
phenotype to be used in the association analysis. 
            44 candidate SNPs identified in the discovery phase of the TNF-α meta-analysis 
were provided by Bram Prin’s group at the University of Groningen. There were 6 SNPs 
already genotyped on the arrays, while the remaining 38 SNPs were imputed using 
IMPUTE2 as described above.  Association tests were performed by SNPTEST (v2.5b) 
[88] using the frequentist association test with additive genotype dosages assumed. 
            Subsequently, I performed a longitudinal analysis, using 815 total measures of 
TNF-α. Excluding samples with no covariate information, 778 total measures remained, 
but of these, 19 ln(TNF-α) measures deviated by more than 4 standard deviation units of 
the mean and were removed. The individuals who only had a single visit were also 
removed. If an individual had more than 3 visits, I used the first 3 visit measures. In the 
end, there were 583 measures from 218 Caucasians (84 men and 134 women). The 
additive genotype dosage was calculated using the formula: dosage=1*pij1+2*pij2. 
Pij1 and pij2 are the probability of genotypes AB and BB corresponding to IMPUTE2 
format with coded allele (the same coded allele as provided by Bram Prin’s group) as 
allele B. A linear mixed effect model in R was performed as 
ln(TNF-α) = μ + genodosage + visit + indivID + age + age2 + BMI + sex + ε 
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where visit is an ordinal variable , indivID is a random effect, μ the grand mean, ε the 
residual error assumed to be normally distributed with a mean of zero, and sex was 
excluded for analyses of women and men separately. 
1000G BMI/CRP Study 
 There were 266 samples whose BMI and CRP and covariates age, sex, BMI were 
all available. They were composed of 204 Caucasians and 62 Africans, age ranging 
between 22 and 76, including 77 males and 189 females. Imputation was performed using 
IMPUTE2 as above. In total, there were 8,970,590 variants (including SNPs and Indels) 
included in the study.  
 CRP ranged from 0.1 to 5.5 mg/L with a mean of 0.39 and a standard deviation of 
0.54. The first step was to perform regression models on ln(CRP) while adjusting for 
covariates. Two regression models were used. The first one was fitting ln(CRP) with 
covariates age, sex, and the first ancestry principle component assessed from the 
genotype matrix. The second model was to fit ln(CRP) with the covariates age, sex, the 
first ancestry principle component as well as BMI. Then association tests were performed 
using the residuals from the two models separately, with imputed genotypes in each 
chromosome. SNPTEST v2 was used to perform the association test on autosomes and 
the X chromosome in females. The study was performed with two methods – “threshold” 
and “expected”, both under additive models. The “threshold” method uses intensity data 
for genotype determinations and was performed with 0.8 as the genotype threshold. The 
“expected” method was performed with expected genotype counts. For the X 
chromosome in males, GWAS was performed in R using a linear model with "threshold" 
and "expected" methods similar to SNPTEST, but with the difference that the "threshold" 
method was performed with 0.5 as genotype threshold (to simply avoid NA in the 




 BMI ranged from 18.4 to 50.9 kg/m2 with a mean of 28.7 and a standard deviation 
of 5.7. BMI was inverse normally transformed (“inBMI”) using the “rntransform” 
function in GenABEL. The regressions on inBMI were performed by adjusting 
covariates, also with two models. The first model was to regress inBMI on covariates 
age, sex, and the first ancestry principle component. The second model was to regress 
inBMI on covariates age, sex, the first ancestry principle component, and lnCRP. The 
association between residuals and genotypes was then performed as for ln(CRP).  
Results 
Imputation 
 Table 3.2 lists the number of imputed SNPs by chromosome based on the 
indicated number of SNPs on the array and number used for imputation after filtering.  As 
seen by contrasting the top and bottom panels, almost identical numbers of imputed SNPs 
were obtained, even though the Batch 1 genotyping quality was lower than Batch 2 
(Table 3.3), due to a problem with reagents.  
 The qualities of imputation were assessed based on quality data given by 
IMPUTE2 such as “info” which represents the imputation certainty and “concordance” 
which shows the concordance between imputed genotypes and original genotypes for one 
SNP.  Table 3.3 summarizes the quality metrics, based on contrast of imputed genotypes 
with a set of masked SNPs, indicating overall concordance over 95% for SNPs with 
MAF<0.05 and 92% for common variants.  Figure 3.1 shows that the confidence in 
imputation increases as MAF increases, as expected, with a plateau after MAF ~ 
0.2.  Figure 3.2 summarizes confidence scores by chromosome showing slight reduction 













1 44,777 18,704 668,341 
2 37,164 18,693 720,978 
3 31,241 15,568 618,134 
4 24,671 13,772 637,124 
5 25,776 13,919 558,284 
6 28,390 14,648 593,657 
7 24,235 12,529 511,581 
8 21,294 12,082 476,431 
9 20,558 10,193 377,977 
10 21,897 11,883 441,860 
11 27,634 11,681 426,805 
12 24,172 11,027 416,516 
13 12,851 8,202 320,765 
14 15,591 7,471 286,850 
15 15,689 6,970 250,060 
16 18,281 7,610 268,571 
17 20,249 6,926 235,730 
18 10,519 6,540 250,195 
19 21,046 5,891 206,783 
20 12,531 6,015 193,171 
21 6,178 3,278 124,885 
22 8,826 3,674 123,724 
X 13,026 7,227 272,090 
Total 486,596 234,503 8,980,512 
 




1 48,430 21,420 668,341 
2 41,224 22,017 720,978 
3 34,656 18,469 618,134 
4 28,550 17,112 637,124 
5 28,894 16,506 558,284 
6 33,678 19,093 593,657 
7 27,039 14,849 511,581 
8 23,840 14,231 476,431 
9 22,681 11,963 377,977 
10 24,059 13,689 441,860 
11 30,020 13,506 426,805 
12 26,540 12,908 416,516 
13 14,900 10,016 320,765 
14 17,156 8,722 286,982 
15 17,020 8,052 250,060 
16 19,434 8,501 268,571 
17 21,346 7,622 235,730 
18 11,951 7,804 250,195 
19 21,910 6,379 206,783 
20 13,380 6,688 193,171 
21 6,887 3,893 124,872 
22 9,215 3,956 123,724 
X 12,675 7,028 267,913 




Table 3.3 Quality metrics for all masked SNPs, dichotomized into groups of MAF < 
0.05 vs. MAF ≥ 0.05. Top: batch I. Bottom: batch II. 
 
MAF (in study samples) Number of SNPs Mean (Median) of 
Overall Concordance 
Mean (Median) of 
empirical dosage r2 
<0.05 9,695 0.96 (0.987) 0.667 (0.759) 
>=0.05 224,808 0.925 (0.954) 0.839 (0.899) 
 
MAF (in study samples) Number of SNPs Mean(Median) of 
Overall Concordance 
Mean(Median) of 
empirical dosage r2 
<0.05 8,935 0.976 (0.987) 0.729 (0.823) 






       
     
Figure 3.1 Summaries of quality metrics at imputed variants: SNPs, SVs, and indels 
in chromosome 12 (chromosome randomly picked, for simplicity). In each plot, 
imputed variants are binned by MAF (0.01 intervals) along the x-axis and then mean 
“info” score per bin is plotted on the y-axis. Left panel is for SNPs and right panel for 
indels and SVs. The secondary y-axes indicate the count of variants in each MAF bin. 
Top: batch I. Bottom: batch II. 
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Figure 3.2 A comparison of imputation quality metrics by chromosome for all 
imputed SNPs. “info” in left panel and “certainty” in right panel for SNPs. Outlier 
values are not displayed in these box plots. On the x-axis, “23” denotes the X 





 Overall, compared to the effect directions reported in the discovery phase meta-
analysis, 30, 25 and 26 out of the 44 SNPs had the same effect direction for baseline 
concentrations of TNF-α in the combined sample, and in men and women, separately.  By 
contrast, 27, 27 and 25 out of the 44 SNPs had the same effect direction for longitudinal 
analyses of the combined sample, and men and women analyzed separately. 
            According to the association significance in the discovery phase, a priority list for 
the replication study was provided by Bram Prin’s group with 11 SNPs in Tier 1 and 9 
SNPs in Tier 2. Table 3.4 shows that all of the significant SNPs in the Tier 1 and Tier 
2 groups (the highest confidence SNPs) had the same effect direction with the meta 
analysis overall direction.  However, rs13112532, which showed the strongest association 
in our cohort, presented in the opposite direction. The association between TNF-α and 
genotype appears to be quite robust in the baseline and longitudinal TNF-α analyses, as 
shown in Figure 3.3.  The top panels show that the relationship between the effect size 
estimates longitudinally and at baseline are always linear, although there is more 




Table 3.4 TNF-a significant association p-values. (-) means opposite direction in 






















2.13E-4(-)  9.35E-4(-)   
rs644234 0.0254 0.0301  0.0215 0.0225  Tier 1 
rs9940180 0.0321  0.0361 0.0321  0.0357   
rs1077462
5 
 0.0421   0.0463    
rs3184504  0.0460   0.0401  Tier 2 
rs1320731
5 
0.0231  0.0132 0.0302  0.0144 Tier 1 
rs4779129 0.0404 0.0321 0.0483 0.0487 0.0354 0.0464   
rs7182229    0.0459  0.0477 Tier 1 




   
     
  
 
Figure 3.3 beta and p-value comparison between TNF-a baseline and longitudinal 
study. Beta comparison in female (A), male (B) and all samples (C). NLP (-log10p) 











 From Table 3.5, BMI has approximately 500 significant associated SNPs (defined 
as p-value < 0.0001) by using either expected or threshold method. CRP has 
approximately 1000 significant associated SNPs by those two methods. Those two 
methods show around 60% overlap in both BMI and CRP studies. In addition, 216 SNPs 
were overlapped between unadjusted expected method and adjusted expected method for 
BMI. 217 SNP were overlapped between unadjusted threshold method and adjusted 
expected method for BMI. As to CRP, the two overlapped SNP numbers were 421 and 
455 respectively. Therefore, the overlapping proportion was approximately 40% for 
unadjusting and adjusting CRP/BMI. There is less than 10 SNPs overlap between SNPs 




Table 3.5  Number of significant SNPs (p-value < 0.0001) for different association 
methods and adjustment models. 
 
  BMI CRP 
adjust CRP unadjust CRP adjust BMI unadjust BMI 
expected 510 473 980 1091 
threshold 476 546 1115 1161 





 There were 10 SNPs found to be associated significantly with TNF-α at 
p<0.05 using 257 Caucasians in the CHDWB cohort. The lack of significant association 
for most of the other 34 SNPs is almost certainly due to the small sample size. However, I 
calculated the HWE_Pvalue for all 44 SNPs with best guess genotype from the 
IMPUTE2 result and observed that rs107744774 (HWE p=3×10-7), rs10892063 (p=1×10-
5), rs17377218 (p=5×10-9) all failed the HWE test, which may have contributed to their 
lack of association detected with TNF-α. 
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            In general, the threshold method detected more significant SNP associations. 
Compared to the expected method, which uses the expected dosage of coded alleles (any 
continuous value between 0 and 2) according to the likelihood of each genotype, the 
threshold method uses the best guess genotype (only 0, 1 or 2 possible). In this way, the 
expected method is more stringent when fitting the models with phenotype. My view is 
that the expected method is more reliable as it takes the likelihood of each genotype into 
consideration and avoids the bias from arbitrary setting of the best guess genotype 
likelihood threshold. 
Preliminary clinical data have suggested TNF-α may be involved in the 
pathogenesis of a variety of human diseases including autoimmune diseases and septic 
shock and inhibition of TNF-α may take a role in disease prevention and treatment [89, 
90]. Anti-TNF-α therapy has been studied for treatment of diseases such as rheumatoid 
arthritis [91]. GWAS on TNF-α would make a better understanding of the genetic basis of 
TNF-α response, and may provide candidate gene targets for pharmacogenetic 
considerations in TNF-α related diseases. Imputation on array genome data has been 
proved to provide a lot of information for GWAS on TNF-α. However, as with the 
development of sequencing techniques, more genetic sites associated with TNF-α 
including rare variants would be likely to be found in future.   
In addition, there are studies showing relationship between the levels of CRP and 
BMI. However, the causal relationship is unclear. The knowledge of genetic variants 
associated with CRP and BMI could play a role in elucidating the causal relationship 
between those two traits with Mendelian randomization, but this is only possible in the 
very large meta-analysis dataset. In addition, CRP is an acute-phase protein, whose level 
rises in response to inflammation and tissue damage [92, 93]. BMI is also a useful 
predictor of health status. It has been shown that many metabolic and disease outcomes 
are related to elevated BMI. For example, coronary artery disease, and type 2 diabetes 
[94, 95] have been found to be more prevalent in people with high BMI. The GWAS 
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analysis of these two traits could therefor provide candidate variants that may have 
implications for development of possible genetic treatment to their related diseases. 
While GWAS analysis on disease-associated traits is very helpful in finding 
genetic positions that are relevant to disease, endophenotype studies such as the ones 
reported in this chapter can also shed light on disease mechanisms and influence drug 
design. This work has shown that genotyping data, in together with imputation of missing 
genotypes, is an efficient way to perform GWAS analysis. However, given the bias and 
incompleteness of genotyping probes, it would be more accurate and more informative if 
sequencing data were used for fine mapping in GWAS.  
According to the results, CRP and BMI have several hundred associated common 
SNPs. The TNF-α discovery phase study found a few hundred candidate SNPs associated 
with the cytokine levels. However, previous studies [96, 97] have shown that hundreds of 
GWAS common SNPs usually only explain less than 20% of the variance. This has also 
been pointed out in Chapter 2. It implies that other factors also contribute to the trait 
variance, for example gene-environment interaction, epigenetic effects, and also rare 
variants, and common variants of very small effect. In the next chapters, I will focus on 




DETAILED SEQUENCING OF 472 PROMOTER REGIONS 
 
Introduction 
 Along with the development of sequencing technologies, genomic variant 
detection has become more and more accessible. The large human genome sequencing 
Consortium projects, such as the 1000 Genomes project, have particularly helped 
researchers gain a deeper knowledge of human genome variation. Improved 
understanding of genomic variant structure has also benefitted our insight into disease 
susceptibility and causation. GWAS have successfully identified thousands of genetic 
variants which show association with common diseases. 
            Common variants that have been detected as being associated with complex 
diseases are known to be considerably more enriched for regulatory than coding variants 
[37, 98-100]. Many analyses utilizing data generated by the ENCODE project have 
shown that specific classes of non-coding variants can have complex impacts on cell 
function and phenotype. According to GWAS analysis, 11% of GWAS hits lie in coding 
regions [101] while 57% of GWAS hits lie in broadly-defined DHS regions which span 
42% of the genome [99]. This implies that non-coding regions have a large impact on 
gene functions and in turn phenotypes, and motivates better understanding of non-coding 
regions.. 
            Here, taking the advantage of targeted resequencing technique, I describe an 
investigation of the distribution of rare variants in promoter regions of 472 genes. In the 
following chapter, I will discuss investigation of the association between cis-acting 
regulatory rare variants and quantitative gene expression traits. In this chapter, the focus 
is on the distribution of rare variants with the aim of generating a more explicit picture of 
genomic variants construction. The analysis includes discussion of the impact of variant 
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calling methods on detection, and comparisons of variant counts between different 
subsets of genes as well as between human populations.  I also include a comparison of 
sequence diversity in regulatory regions versus in coding regions, taking advantage of 
public available 1000 Genomes data, and  between genes which are thought to be 
disease-related (or potentially disease-related) and genes which do not harbor disease 
SNPs. 
            A genome-wide scoring system called (Residual Variation Intolerance Score) that 
ranks human genes in terms of their intolerance to standing functional genetic variation in 
the human population was introduced by Petrovski et al [102]. They used empirical single 
nucleotide variant data from the NHLBI Exome Sequencing Project and ranked the genes 
based on whether they have more or less functional genetic variation relative to the 
genome wide expectation. Their work has shown that the genes which harbor fewer or 
more common functional variants may be more or less prone to cause certain kinds of 
diseases in healthy individuals. Here, I utilized the targeted sequencing data to detect the 
intolerance of rare variants in promoter regions and compared the results with Petrovski 
et al’s result with respect to disease-related genes. 
 Benefitting from the accessible genotyping and expression data of the CHDWB 
study cohort, eQTL analysis was performed. I investigated the rare variant distribution in 
genes with strong common eQTL and genes without common eQTL. As studies have 
shown that trait – associated SNPs are more likely to be eQTLs, the genes that show a 
strong signal of eQTL are more likely to be correlated with diseases. In this way, 
comparing the rare variant counts in promoter regions shows the intolerance of rare 
variants between different potential disease – associated gene status. 
            I also used Metabochip and Immunochip identities to investigate the difference of 
intolerance to rare variants in promoter regions in different gene sets. The “Metabochip”, 
a custom Illumina iSelect genotyping array, was designed for the genome-wide 
association tests of diseases and traits relating to metabolic, atherosclerotic and 
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cardiovascular traits [103]. It contains approximately 200,000 SNPs including variants 
with low frequency identified by the 1000 Genomes project. Similarly, the 
“Immunochip” is an Illumina Infinium SNP array which was designed for association 
studies of autoimmune and inflammatory diseases [104]. The genes which harbor SNPs 
represented on the Metabochip are with high probability related to metabolic disease, 
atherosclerosis, and cardiovascular diseases, while, the genes which harbor SNPs on the 
Immunochip are potentially related to autoimmune and inflammatory diseases. 
            While different sequencing techniques and platforms will lead to different 
sequencing qualities, affecting variant calling accuracy, different variant calling 
algorithms could also affect the variant calling result enormously. The commonly used 
software packages for variant calling include the Genome Analysis Toolkit (GATK) [17], 
SOAPsnp [105], VarScan [19], and ATLAS [106]. Here I compared GATK and VarScan. 
Developed by the Broad Institute, GATK is one of the most popular methods for variant 
calling using aligned reads. It is designed in a modular way and is based on the 
MapReduce functional programming approach. Developed by the Genome Institute at 
Washington University in St. Louis, VarScan is an open source tool for short read variant 
detection of SNPs and indels that is compatible with multiple sequencing platforms and 
aligner algorithms such as Bowtie [14] and Novoalign (http://novocraft.com). Some 
variants were then verified by the “gold standard” method of Sanger sequencing. 
 Accurate detection of rare variants also requires that the read depth should be high 
enough to avoid false positives caused by sequencing errors and false negatives caused 
by insufficient coverage to detect heterozygotes. The ideal alternate allele proportion 
is 0.5 for heterozygous site, and 1 for homozygous site. Figure 4.1 shows the alternate 
allele proportion over read depth of the bases. It shows that the alternate allele proportion 
is consistently approximately 0.5 or 1 when the read depth is larger than 100. This 
empirically demonstrates that high read depth is also appropriate and necessary in a study 









  The variant profile was expected to be somewhat different among different genes 
and populations. Analysis of the 1000 Genomes project phase I based on 1092 sample 
whole genome sequencing data, common and rare variants all show different distributions 
among populations. More than 50% of rare variants (MAF less than 5%) were observed 
in just a single population. Furthermore, rare variants detected in individuals with African 
ancestry were three times as prevalent as those in individuals of European or East Asian 
origin. In addition, individuals from all populations showed an enrichment of rare 
variants relative to some classes of neutral evolutionary model, which has been attributed 
to population size explosion and accompanying geographic differentiation [107, 108]. 
Materials and Methods 
410 Samples 
The 410 Samples included in this study are listed in Table 4.1. They were 
composed of 297 Caucasian Americans, 85 African Americans and 18 Asian Americans. 
There were 274 females and 136 males. Age ranged from 19 to 83 with an average of 50. 
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Table 4.1 Anthropomorphic information for the 410 samples. 
ID AGE GENDER ANCESTRY ID AGE GENDER ANCESTRY ID AGE GENDER ANCESTRY 
Sample1 51 F AFR Sample138 63 F CAU Sample275 48 M CAU 
Sample2 52 M CAU Sample139 48 F CAU Sample276 46 M CAU 
Sample3 50 M CAU Sample140 63 M CAU Sample277 52 M CAU 
Sample4 60 F CAU Sample141 48 F CAU Sample278 61 F CAU 
Sample5 59 F CAU Sample142 47 M ASN Sample279 39 M CAU 
Sample6 69 F CAU Sample143 40 F CAU Sample280 45 F AFR 
Sample7 46 M CAU Sample144 59 F CAU Sample281 41 F CAU 
Sample8 55 F AFR Sample145 48 F AFR Sample282 61 F CAU 
Sample9 57 F AFR Sample146 59 F CAU Sample283 49 F AFR 
Sample10 37 M CAU Sample147 58 M AFR Sample284 55 F CAU 
Sample11 59 M CAU Sample148 33 M CAU Sample285 46 F AFR 
Sample12 44 F CAU Sample149 36 F CAU Sample286 29 F CAU 
Sample13 42 F AFR Sample150 66 M CAU Sample287 45 F AFR 
Sample14 61 F CAU Sample151 53 F ASN Sample288 47 M AFR 
Sample15 49 F AFR Sample152 63 F AFR Sample289 47 F AFR 
Sample16 50 F CAU Sample153 65 M CAU Sample290 40 M CAU 
Sample17 56 M CAU Sample154 52 F AFR Sample291 52 M CAU 
Sample18 59 F AFR Sample155 37 F CAU Sample292 49 F AFR 
Sample19 52 F CAU Sample156 43 M AFR Sample293 53 F CAU 
Sample20 61 M CAU Sample157 34 F AFR Sample294 53 F CAU 
Sample21 54 M CAU Sample158 40 F CAU Sample295 35 F CAU 
Sample22 54 F AFR Sample159 79 M CAU Sample296 54 F CAU 
Sample23 53 F AFR Sample160 70 M CAU Sample297 47 M CAU 
Sample24 55 F CAU Sample161 30 F CAU Sample298 50 F AFR 
Sample25 54 F CAU Sample162 43 F AFR Sample299 51 F CAU 
Sample26 54 F AFR Sample163 59 M CAU Sample300 31 F CAU 
Sample27 60 F CAU Sample164 47 M CAU Sample301 44 F AFR 
Sample28 47 F CAU Sample165 58 M CAU Sample302 68 F CAU 
Sample29 56 M CAU Sample166 51 M ASN Sample303 57 M CAU 
Sample30 53 F CAU Sample167 50 F AFR Sample304 56 M ASN 
Sample31 59 F CAU Sample168 50 F ASN Sample305 66 M CAU 
Sample32 57 M CAU Sample169 54 F AFR Sample306 48 F AFR 
Sample33 60 M CAU Sample170 49 F AFR Sample307 56 F AFR 
Sample34 48 M CAU Sample171 40 F CAU Sample308 59 F CAU 
Sample35 36 F AFR Sample172 46 F CAU Sample309 51 F AFR 
Sample36 54 F CAU Sample173 64 F CAU Sample310 54 F CAU 
Sample37 59 F AFR Sample174 44 F CAU Sample311 51 M CAU 
Sample38 48 F CAU Sample175 54 F CAU Sample312 62 F AFR 
Sample39 55 M CAU Sample176 60 M CAU Sample313 59 M CAU 
Sample40 40 F CAU Sample177 55 M CAU Sample314 57 M CAU 
Sample41 31 F CAU Sample178 52 F CAU Sample315 58 M AFR 
Sample42 35 F AFR Sample179 75 M CAU Sample316 35 F CAU 
Sample43 36 F CAU Sample180 57 F CAU Sample317 48 F CAU 
Sample44 50 F AFR Sample181 53 F AFR Sample318 55 F CAU 
Sample45 50 M CAU Sample182 49 F AFR Sample319 56 F CAU 
Sample46 36 F CAU Sample183 64 M CAU Sample320 46 M CAU 
Sample47 52 F ASN Sample184 41 M CAU Sample321 55 F CAU 
Sample48 58 F CAU Sample185 57 M CAU Sample322 55 F ASN 
Sample49 33 F CAU Sample186 41 F CAU Sample323 40 F CAU 
Sample50 37 F AFR Sample187 43 M AFR Sample324 57 F CAU 
Sample51 55 M CAU Sample188 48 F AFR Sample325 63 M CAU 
Sample52 59 M CAU Sample189 55 F AFR Sample326 41 F AFR 
Sample53 52 F CAU Sample190 45 M CAU Sample327 60 M CAU 
Sample54 57 M CAU Sample191 58 M CAU Sample328 26 M CAU 
Sample55 41 M CAU Sample192 57 M CAU Sample329 56 F CAU 
Sample56 59 F CAU Sample193 66 F CAU Sample330 19 M ASN 
Sample57 50 F AFR Sample194 57 M CAU Sample331 60 M CAU 
Sample58 60 F CAU Sample195 41 F CAU Sample332 53 F CAU 
Sample59 60 F CAU Sample196 64 F CAU Sample333 61 F CAU 
Sample60 29 F AFR Sample197 39 F CAU Sample334 59 F CAU 
Sample61 56 F AFR Sample198 39 F CAU Sample335 44 M CAU 
Sample62 74 M CAU Sample199 29 M CAU Sample336 66 M CAU 
Sample63 55 F CAU Sample200 52 M CAU Sample337 49 M CAU 
Sample64 37 F CAU Sample201 47 M ASN Sample338 71 F CAU 
Sample65 50 F CAU Sample202 37 M CAU Sample339 41 M CAU 
Sample66 59 F CAU Sample203 56 F CAU Sample340 50 F CAU 
Sample67 46 F CAU Sample204 66 M CAU Sample341 42 M CAU 
Sample68 58 M CAU Sample205 40 F AFR Sample342 44 F CAU 
Sample69 31 F CAU Sample206 35 F CAU Sample343 41 F CAU 
Sample70 58 M CAU Sample207 83 M CAU Sample344 36 F AFR 
Sample71 57 M CAU Sample208 38 F CAU Sample345 50 F CAU 
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Table 4.1 (continued) 
Sample72 68 F CAU Sample209 67 M CAU Sample346 59 M ASN 
Sample73 69 M CAU Sample210 45 F AFR Sample347 45 F CAU 
Sample74 47 F CAU Sample211 56 F AFR Sample348 57 M CAU 
Sample75 79 F CAU Sample212 51 F CAU Sample349 41 F CAU 
Sample76 56 F AFR Sample213 34 F CAU Sample350 46 F CAU 
Sample77 42 M CAU Sample214 31 F CAU Sample351 46 F AFR 
Sample78 56 F CAU Sample215 54 F CAU Sample352 44 M CAU 
Sample79 44 F CAU Sample216 59 F AFR Sample353 37 F AFR 
Sample80 53 M CAU Sample217 63 F CAU Sample354 37 F CAU 
Sample81 57 F CAU Sample218 53 F CAU Sample355 38 F CAU 
Sample82 57 F CAU Sample219 44 F AFR Sample356 37 M CAU 
Sample83 50 F CAU Sample220 50 F CAU Sample357 36 F CAU 
Sample84 46 M CAU Sample221 40 F CAU Sample358 51 M CAU 
Sample85 35 F CAU Sample222 54 M CAU Sample359 37 F CAU 
Sample86 48 F CAU Sample223 61 M CAU Sample360 45 F AFR 
Sample87 45 F AFR Sample224 55 F CAU Sample361 35 F CAU 
Sample88 39 F CAU Sample225 55 M AFR Sample362 61 F CAU 
Sample89 54 F AFR Sample226 54 F CAU Sample363 57 M CAU 
Sample90 42 M ASN Sample227 20 F AFR Sample364 62 M CAU 
Sample91 37 F CAU Sample228 65 F CAU Sample365 42 F CAU 
Sample92 49 F CAU Sample229 53 M AFR Sample366 59 M CAU 
Sample93 40 M CAU Sample230 57 F CAU Sample367 44 F CAU 
Sample94 55 F ASN Sample231 43 F CAU Sample368 53 M CAU 
Sample95 57 M AFR Sample232 43 M CAU Sample369 43 F CAU 
Sample96 49 F AFR Sample233 57 F CAU Sample370 28 F CAU 
Sample97 35 F AFR Sample234 55 F AFR Sample371 58 M CAU 
Sample98 35 F AFR Sample235 37 F CAU Sample372 55 F CAU 
Sample99 46 M ASN Sample236 54 M CAU Sample373 39 F CAU 
Sample100 47 F AFR Sample237 49 F CAU Sample374 66 M CAU 
Sample101 36 M CAU Sample238 74 F CAU Sample375 55 M CAU 
Sample102 61 F CAU Sample239 50 F CAU Sample376 54 F CAU 
Sample103 62 F CAU Sample240 49 F CAU Sample377 52 F CAU 
Sample104 53 F CAU Sample241 54 F CAU Sample378 42 F CAU 
Sample105 50 M ASN Sample242 29 M CAU Sample379 53 M CAU 
Sample106 60 M CAU Sample243 26 F AFR Sample380 58 F CAU 
Sample107 63 M CAU Sample244 30 F AFR Sample381 55 M CAU 
Sample108 68 F CAU Sample245 36 F CAU Sample382 39 F CAU 
Sample109 31 F AFR Sample246 26 M ASN Sample383 63 F CAU 
Sample110 38 F AFR Sample247 54 F CAU Sample384 53 F AFR 
Sample111 55 M CAU Sample248 56 M CAU Sample385 63 M CAU 
Sample112 32 F CAU Sample249 49 M CAU Sample386 19 F AFR 
Sample113 56 F CAU Sample250 43 M ASN Sample387 50 F CAU 
Sample114 53 F AFR Sample251 47 F AFR Sample388 55 F CAU 
Sample115 40 F CAU Sample252 58 M CAU Sample389 57 F CAU 
Sample116 58 F CAU Sample253 37 M AFR Sample390 58 F CAU 
Sample117 39 M CAU Sample254 55 F AFR Sample391 49 F CAU 
Sample118 37 F CAU Sample255 57 M CAU Sample392 45 F CAU 
Sample119 64 M CAU Sample256 62 F CAU Sample393 36 M CAU 
Sample120 42 F AFR Sample257 60 F CAU Sample394 45 F AFR 
Sample121 43 M CAU Sample258 65 M CAU Sample395 44 F CAU 
Sample122 50 F CAU Sample259 48 F AFR Sample396 48 F AFR 
Sample123 35 M CAU Sample260 46 F CAU Sample397 43 F CAU 
Sample124 47 F AFR Sample261 35 F CAU Sample398 64 F CAU 
Sample125 53 M CAU Sample262 59 F CAU Sample399 60 M CAU 
Sample126 59 F AFR Sample263 61 F AFR Sample400 36 F CAU 
Sample127 34 F CAU Sample264 22 M CAU Sample401 54 F CAU 
Sample128 61 F AFR Sample265 58 M CAU Sample402 57 F CAU 
Sample129 28 M CAU Sample266 59 F AFR Sample403 52 F AFR 
Sample130 66 F CAU Sample267 30 F AFR Sample404 56 M CAU 
Sample131 41 M AFR Sample268 65 F CAU Sample405 54 F AFR 
Sample132 47 F CAU Sample269 62 F CAU Sample406 36 F AFR 
Sample133 54 F CAU Sample270 55 F CAU Sample407 55 M CAU 
Sample134 48 M CAU Sample271 39 F CAU Sample408 40 F CAU 
Sample135 49 F CAU Sample272 41 F AFR Sample409 56 F ASN 
Sample136 58 F AFR Sample273 39 F ASN Sample410 59 F CAU 





            Table 4.2 lists the genes, which were selected based on the idea of having genes 
harboring common cis-eSNPs (and hence established to be genetically regulated), a 
subset of these also having a high probability of being related with disease traits, with the 
remainder being control genes. The common cis-eSNP results were based on imputed 
genotyping results from analyses described in the previous chapter. I also took advantage 
of Metabochip and Immunochip arrays to choose the gene that have Metabochip or 
Immunochip SNPs in the vicinity so that the genes had a high probability to be involved 
in some diseases or traits.  The gene selection was performed in August 2012, but cis-




Table 4.2 The 472 genes selected in the study. 
 
ACADM ACER3 ADCK3 ADK ANXA11 AOAH B4GALT4 BTN3A2 CARD8 CARD9 
CDA CDK10 CFDP1 CTSH CWF19L1 DNAJC15 DR1 FCER1G FDFT1 GAPT 
GATAD2A GATS GNA12 HIST1H2BD HPS1 HSD17B12 IQCB1 ITGAX KCTD10 KIAA0368 
KLHDC4 MBNL1 MED16 MFN2 MSRA MTMR3 NT5C3 ORMDL3 PASK PDCD4 
PTGS2 RFWD3 RPA1 SF3A3 SIDT2 SIRPB1 SIRPG SLC39A8 SLC40A1 SMAP1 
SNX29 SP110 SPNS1 SUMF1 TATDN2 TBC1D15 TOMM7 TRAK1 TRPC4AP TUFM 
UBE2L3 UGDH USP48 XRCC6BP1 ADSS ALDH2 ALPL APOL3 ARID5B ARPP19 
C1orf38 CD96 CDAN1 CLN3 CPPED1 CRISPLD2 CTDSP1 CTNNAL1 CTSO DDX52 
DEF6 DHRS3 DHX38 DIAPH2 DLAT DOCK10 DOCK11 E2F6 ECHS1 EIF4G3 
EPB41 EXOC4 F13A1 FAM49A FAR2 GAB3 GMCL1 GNPAT HBP1 HSPA4 
IL18R1 IQGAP1 ITGAM ITK KIAA0319L LILRB2 LMAN2L LMNA LRPPRC M6PR 
MAN2A2 MBNL2 MSI2 NEDD9 NUDT5 OXR1 PDK3 POR RBBP4 RNF130 
RNPS1 SERTAD2 SH2D1B SNX14 SRP54 STAT3 STAT4 SUSD3 TAF1C TAF1L 
TBC1D2B TMEM175 TPM1 TSSC1 UBR2 UQCC USO1 USP4 VIM WDFY2 
ZAK ZDHHC17 ZMIZ1 ZNF185 ZNF407 ABCC5 ACOX1 ACP2 ALS2 ATP13A1 
C12orf35 C14orf102 C1orf86 C2orf28 C7orf25 CEP63 CRLS1 DHRS1 DUS2L EEF1G 
EMR3 ERP27 FEZ2 FN3KRP FXYD5 HDDC2 KIAA1598 LACTB LDLRAP1 LINS 
MAU2 MEFV MGST3 MRPS21 NSFL1C PCMTD2 PIGQ PYGB RNF181 RPL13 
RPS6KB2 RUFY1 SAMM50 SENP2 SF3A1 STAT6 STYXL1 SURF6 TAGLN TMEM140 
VAMP1 VAMP8 VASP VEZT ZMIZ2 IPP FCRL3 AHSA2 CAPG ASNSD1 
UBA7 HCLS1 SRI KRIT1 TRIM4 PILRB ZYX TNFSF8 RRP12 ZRANB1 
PRDX5 ALDH3B1 FAM76B TRAPPC4 PEX5 PWP1 POLR1D ACTR10 GALC CLCN7 
DCTN5 GDPD3 ZFP90 CXCL16 SMARCE1 ZNF266 LRRC25 PLAUR SYS1 LTN1 
XBP1 ACTR6 ALKBH1 ASXL2 ATMIN BSDC1 C14orf179 C2orf44 C6orf129 DNAJC8 
E2F2 EIF2AK4 ERCC3 FBXO11 HADH HNRNPC HSPA9 ID3 ILF3 LARP4 
LASS5 LFNG MED22 MRPL17 MSH6 MYC NDUFB10 NEDD8 NUFIP2 OGFOD1 
OGFRL1 PACSIN2 PFDN1 PHF21A PIP4K2B PRRC1 RAB11FIP2 RAB8B RHOT1 RNF135 
SERPINB8 SESN3 SHROOM4 SLC35A3 STARD3NL TRAF5 TSPAN33 UBN1 ZNF787 ZNF839 
CPSF3L MOBKL2C SLC27A3 SLAMF7 TRAF3IP3 MKI67IP ICOS FRG1 DHX29 BRD8 
DKFZp686I15217 TDP2 KATNA1 STOM C9orf114 COBRA1 RPP38 HNRNPH3 SLC3A2 HSPA8 
C12orf32 TUBA1B ADPGK SNRNP25 EIF4A1 STAT5A C18orf21 VPS4B RANBP3 GTF2F1 
TMEM149 ALDH16A1 ZNF613 ADRM1 HSCB TLR7 GSPT2 ATG4A NAA10 ABHD10 
ARL16 ATP5J2 ATP5S ATPIF1 C14orf129 C17orf90 C1orf85 C8orf40 C9orf78 CALR 
CAT CCDC23 CCDC88B CIB1 CKS2 CRIPT CXCL5 DCXR DSTYK EIF2B2 
EIF5 EPHX2 ETS2 EVI2A GPATCH4 GPX7 H1F0 HEBP2 IKBIP IL8 
KIAA1737 LIPT1 MAD2L1BP MR1 MRPL34 MRPL43 MRPL52 MRPL53 NOP10 NUDT18 
NUDT2 NUP43 ORMDL1 PIGN PPIL3 PRKAR1A PTGDR RPL14 RPL36AL RPUSD4 
RRM2B SNAP29 TAPBPL TFG TRAPPC5 TRAPPC6B ABHD8 ACAA2 AKR7A3 ALPP 
AP1G2 AP1S1 ARAF ARGLU1 AZI2 BEX2 BFAR BIRC3 BRF2 BRMS1 
BTK C11orf17 C14orf142 C15orf63 C18orf10 C1orf123 CD160 CHRNB1 CIDECP COMMD4 
COMMD7 COMMD9 CUL4B CXXC5 DDOST DDX41 DGUOK DRAM1 EBP ECH1 
EIF1AX EIF2S3 FAM193B GPAA1 GRK6 HARS2 HBQ1 HDHD1 HIF1AN HSD17B11 
HSP90AB1 KIAA1191 KLF4 LAPTM5 LONP2 LRRCC1 MAF1 MAGEH1 MAPK1IP1L MPHOSPH10 
MPL NFE2L1 NONO PCNA PDCD2 PEA15 PFN1 PIGH PPCS RAB10 
RAB24 RBMX2 RCE1 RPL10A RPL4 RPL9 RPUSD3 SCAND1 SDAD1 SERTAD1 
SETD3 SF3B4 SHCBP1 SNORA70 TCEAL8 TFE3 THAP7 TMEM199 TNFRSF4 TUBA1A 
TXNIP UBL4A UTP18 UXT WAS WDR45 YIF1A YIPF3 ZNF439 ZNF549 





 The 472 genes have been classified into 8 groups, color coded in Table 4.2, 
according to the following criteria:  
1) Genes which have both Metabochip and Immunochip SNPs, and have cis-eSNPs 
inside the gene body and in the promoter regions. These 64 genes are marked as red in 
Table 4.1.  
2) Genes which have both Metabochip SNPs and Immunochip SNPs inside the gene body 
and in the promoter regions, but don’t have common cis-eSNPs. These 81 genes are 
marked as purple.  
3) Genes which have Metabochip SNPs and common cis-eSNPs inside the gene body and 
in the promoter regions, but don’t have Immunochip SNPs in the vicinity. These 50 genes 
are marked as green.  
4) Genes which have Immunochip SNPs and common cis-eSNPs inside the gene body 
and in the promoter regions, but don’t have Metabochip SNPs in the vicinity. These 36 
genes are marked as blue.  
5) Genes which have Metabochip SNPs inside the gene body and in the promoter regions, 
but don’t have either Immunochip SNPs or common cis-eSNPs in the vicinity. These 49 
genes are marked as orange.  
6) Genes which have Immunochip SNPs inside the gene body and in the promoter 
regions, but don’t have either Metabochip SNPs or common cis-eSNPs in the vicinity. 
These 39 genes are marked as dark blue.  
7) Genes which have common cis-eSNPs inside the gene body and in the promoter 
regions, but don’t have either Metabochip SNPs or Immunochip SNPs in the vicinity. 
These 57 genes are marked as yellow.  
8) 96 randomly chosen genes from which without harboring common cis-SNPs or having 
Metabochip or Immunochip SNPs in the vicinity. They are marked as black. 
 In summary, 207 genes have common cis-eSNPs in the gene body or in the 
promoter regions. 244 genes have Metabochip SNPs in the vicinity while 220 genes have 
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Immunochip SNPs nearby.  
Targeted Sequencing 
            Whole genomic DNA was isolated from buffy coats of 410 CHDWB samples 
using Flexigene DNA kits (QIAGEN, Valencia, CA). The major transcription start site 
(TSS) of each gene was extracted from the UCSC Genome Browser and oligonucleotide 
probes were designed using the Illumina Design Studio so as to pull down 1kb upstream 
and 1kb downstream of the major TSS for each of the 472 genes. 5 oligonuceotide probes 
were designed per each gene to ensure that the percentage of the total length of all 
regions targeted for enrichment was not less than 90%. Sequence capture libraries were 
generated and pooled using Illumina TruSeq DNA Sample Preparation Kits and TruSeq 
Custom Enrichment Kits. The sample preparation steps included DNA shearing with 
Covaris to an average size of 300bp, conversion of the overhangs after fragmentation to 
produce blunts ends, adenylation of 3’ ends to prevent fragments ligating to each other, 
ligation of indexing adapters to the ends of DNA fragments, and amplification of the 
adapter-ligated DNA fragments by PCR. The quality of each library was assessed on an 
Agilent Bioanalyzer 2100, and the DNA concentration was quantified with a Qubit. 
Samples were pooled in groups of 12 samples, and TruSeq Enrichment was performed 
including two rounds of hybridization with capture probes of the targeted regions on 
streptavidin beads. Subsequently, the pooled DNA libraries were amplified with PCR, 
and 24 samples (two of the 12-plex pull-downs) were pooled together and quantified by 
real time-PCR. Paired end 100bp sequencing was performed on an Illumina HiSeq 2500 
at Georgia Tech. 
 FastQC Information 





Figure 4.2 Quality score across all bases. The background divides the quality into three 
bins by colors. Green: very good quality calls. Orange: reasonable quality calls. Red: 
poor quality calls. The central red line represents the median value. The yellow box 
shows the inter-quartile range with the upper and lower whiskers representing 




 Figure 4.2 shows that for most of the reads except for the last few bases, the 
quality scores are very high, representing good calling quality. It is common to see base 
calls falling into the reasonable quality orange area, or even the poor quality red area, 






Figure 4.3 Qualtity score distribution over all sequences. The average quality scores 
per read uses Phred score.  
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 From Figure 4.3, it can be seen that over 95% of the reads have high quality 
scores which are larger than 28. The Phred quality score = -10log10P where P represents 
the error rate, shows that most of the reads have an error rate less than 0.16%. 
Furthermore, in Figure 4.4, the lines run parallel with and very close to each other, 
indicating that there is little difference between the proportions of A, G, T and C bases. 
The lines are flat across different positions in read, also showing the base proportion does 
not differ between different positions, as expected of high quality and unbiased data.     
     
 
              
 





 Finally, Figure 4.4 shows that the GC counts per reads do not deviate from the 
normal distribution, indicating that the library is normal random.  The blue line is the 
theoretical GC content distribution. The red line represents the real GC content across the 
whole length of each sequence. 
Variant Calling Method Comparison 
 Variant calling method comparison was implemented in the first batch of 
sequences, which had 12 samples. 
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Following short read alignment with BWA, three different algorithms for variant 
calling were evaluated.  First, the BWA aligner was used to align fastq files to hg19.  
Next, Samtools was used to pileup .bam files, with a minimum mapping quality of 10, 
coverage of 20, and per base quality of 15, and then VarScan was used to call all variants 
with a minimum alternate allele proportion of 0.25.  Alternatively, GATK version 2.7 was 
used to call variants relative to hg19, marking duplicates with Picard, realigning around 
known indels and recalibrating around known SNPs according to recommendations for 
users.  UnifiedGenotyper and HaplotypeCaller were run separately, both with emission 
confidence of 10 and calling confidence of 50.  I then applied a hard filter to call variants 
with QD>=2, FS<=60, MQ>=40, HaplotypeScore<=13, MQRankSum>=-12.5, 
ReadPosRankSum>=-8 based on GATK best practice. 
 Given differences in polymorphism call rates as much as 30% between the 
algorithms, with a notable deficiency of variants observed using VarScan (Figure 4.7), I 
decided to adopt the more theoretically validated Bayesian strategy implemented in 
GATK for rare variant inclusion.  The rare variants were identified in this study with 
minor allele frequency (MAF) less than 0.05 in those 410 samples.  
Rare Variant Comparison Among Sample Subgroups And Gene Subsets 
 The number of rare variants were compared between different sample subgroups 
based on ancestries and genders, and also between different gene subsets based on 
whether the genes harbor common cis-eQTLs, whether they were potentially related with 
diseases, and also between different positions with respect to TSS and RegulomeDB 
classes. Metabochip and Immunochip were used to classify the genes with respect to 
disease relatedness. There were 196,293 SNPs in the Metabochip array and 196,450 
SNPs in the Immunochip array, of which 11,621 SNPs occurring on both the Metabochip 
array and the Immunochip array. There were 2,936 SNPs in the 244 of our 472 genes that 
are on the Metabochip array that are in the gene body and 1kb upstream of the TSS. 
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Similarly, there were 3,778 SNPs on the Immunochip array that were in the gene body 
and 1kb upstream of TSS of the 220 of 472 genes. Of these, 153 SNPs occurred in the 
gene body and upstream region of 472 genes for both arrays. There were 146 genes that 
have both Metabochip SNPs and Immunochip SNPs around the genes, and 319 genes that 
are represented on at least one of the Metabochip or Immunochip SNPs. 
Nucleotide Diversity Calculation and Comparison 
 Nucleotide diversity (π) in promoter region was calculated based on common 
variants and rare variants called by targeted resequencing with CHDWB Caucasian data. 
Nucleotide diversity in coding region was calculated based on 1000 Genomes release 
version 20130502 European data. The coding regions of 472 genes were obtained from 
UCSC Genome Browser. Nucleotide diversity were calculated using VCFtools [109] with 
each variant position. And then summed π’s were divided by the region size to generate 
averaged per site π. As coding regions sometimes overlap with the 2kb promoter regions 
and hence these diversity estimates are not independent, I also calculated averaged 
nucleotide diversity for the regions 1kb upstream of each TSS based on Caucasians in the 
CHDWB cohort.  
Results 
Overall Summary of Sequence Distribution 
 The overall sequencing information was obtained after aligning sequencing fastQ 
files with BWA (with BWA mem), and then running SAMtools flagstat on the BAM files 
after fastQ. For the 410 samples, the total reads ranged from approximately 2 million to 
40 million, with a mean of 14 million and a standard deviation of 5 million. The mapped 
reads proportion was within 94.08% and 99.92% with a mean of 99.33% and a standard 
deviation of 1.05. The properly paired reads ranged from 92.95% to 98.95% with a mean 




        
 
Figure 4.5 The distribution of A. total reads B. mapped reads proportion (%) C. 




 Various data quality checks were performed.  Approximately 75% of the aligned 
reads were mapped to the 2kb promoter regions of the 472 genes, indicating good 
enrichment to the targeted regions. The average read depth across the dataset was more 
than 600X, with over 90% of the genes having more than 80% reads of the 2kb promoter 
regions having more than 20X read depth (Table A.1).  Due to the nature of the pull-
downs, in many cases an extra 500 bp was recovered, but for consistency I restricted our 
analysis to 1kb upstream and 1kb downstream of each major TSS.   
Figure 4.6 shows the read depth distribution across the 2kb promoter regions in 
TNFRSF4. The 5 peaks clearly show 5 probes covering the gene. Over 90% of the 










Figure 4.6 The read depth distribution across the promoter regions of TNFRSF4. 
Green triangle: rare SNPs. Blue triangle: common SNPs. Red horizontal dashed line: 20x 




Comparison of Different Variant Calling Algorithms 
 For comparison of the different calling algorithms, consider one sample for whom 
the number of SNPs within promoter regions called by different variant calling methods 
was 679 SNPs called by the Samtools/Varscan method and 1007 SNPs and 903 SNPs 
respectively called by HaplotypeCaller and UnifiedGenotyper. The Venn diagrams below 
show the overlap among methods for this one individual.  HaplotypeCaller is reported to 
have a higher sensitivity and lower false positive rate than UnifiedGenotyper, and clearly 












 To quantify the effect of the nature of the reference template on the variant 
calling, I compare the SNPs called by Varscan with hg19 or with just the targeted 2kb 
promoter regions from hg19 as the references, for 12 samples. From Table 4.3, 
approximately twice as many SNPs were called with the targeted regions as the reference, 
compared to ones called with the whole hg19 genome as the reference. The excess SNPs 
had relatively high read depth, and only a few SNPs that were called with hg19 whole 
genome as the reference were not called with targeted regions as the reference, in which 
case those SNPs showed relatively low read depth. A probable explanation of this 
phenomenon is that some reads mapped better elsewhere in the genome, but were forced 
to map to similar sequences in the targeted regions. Consequently, when only using the 
targeted regions as the reference, those reads were incorrectly mapped to the targeted 
regions, resulting in false positive calls. 
65 
 
Table 4.3 Comparison of Varscan called SNP counts when aligning with hg19 and 
targeted regions respectively as reference for 18 samples.  
 






sample_ID # of 
SNPs 










avg rd # of 
SNPs 
avg rd 
Sample 1 681 570 1155 605 671 584 485 635 10 252 
Sample 2 751 616 1303 612 743 630 561 586 8 285 
Sample 3 702 623 1234 635 692 636 544 631 10 329 
Sample 4 704 740 1442 643 695 751 747 544 9 340 
Sample 5 551 690 1169 650 545 705 624 602 6 196 
Sample 6 683 531 1399 497 676 535 723 456 7 201 
Sample 7 741 764 1569 660 733 766 836 556 8 573 
Sample 8 677 497 1186 515 666 501 521 523 11 240 
Sample 9 751 662 1273 668 732 665 541 653 19 562 
Sample 10 823 627 1318 659 810 633 508 695 13 234 
Sample 11 730 739 1295 746 719 744 575 728 11 366 
Sample 12 683 598 1200 602 671 604 530 592 12 265 
Sample 13 709 819 1702 960 701 825 1003 1045 8 304 
Sample 14 685 613 1606 817 665 623 942 932 20 286 
Sample 15 750 658 1647 862 731 669 918 1000 19 199 
Sample 16 722 575 1582 757 709 581 875 878 13 213 
Sample 17 755 748 1676 963 737 760 941 1106 18 252 
Sample 18 753 795 1733 991 743 803 991 1116 10 247 
* “SNP_hg19” means SNPs called with hg19 whole genome as the reference genome.  
* “SNP_Targeted” mean SNPs called with targeted regions as reference.  
* “SNPs in common” means the SNPs which are called with hg19 as reference are also called with targeted 
regions as reference.  
* “Targeted-hg19 SNP” means the SNPs are called with the reference of targeted regions, but not called 
with hg19 as the reference.  
* “hg19-Targeted SNP” is the other way around.  





Since the UnifiedGenotyper algorithm is more suited to joint mapping of a large 
dataset with GATK version 2.7, the release I used in 2013, namely where all reads are 
aligned together as opposed to combining the results of individual mapping, I decided to 
use it for the final rare variant calling.  Pooling is expected to control the false positive 
rate, and it was infeasible to run HaplotypeCaller on the 472 samples on our cluster. The 
UnifiedGenotyper final processing on 24 nodes used 17Gb of memory and ran for over 
37 hours.  After variant calling, the GATK VQSR tool was used for further variant 
filtering using the Illumina Omni chip array based on the 1000 Genomes Project as the 
training data with the highest confidence SNPs from the 1000 Genomes Project's callset 
used to validate the SNPs. The filtering criteria included QD (quality by depth ratio), DP 
(depth), FS (Fisher’s exact test of strand bias) , ReadPosRankSum (Mann-Whitney Rank 
Sum Test for the distance of reads with the alternate allele to the end of the read), 
MQRankSum (Mann-Whitney Rank Sum Test for mapping qualities) and 
InbreedingCoeff (likelihood-based test for the inbreeding among samples). The Venn 
diagram in Figure 4.8 shows the number of SNPs in one sample called by 
UnifiedGenotyper batch calling followed by VQSR filtering, in comparison with 
HyplotypeCaller, and with UnifiedGenotyper on the sample alone followed by hard 
filtering. Both UnifiedGenotyper and HyplotypeCaller have good overlap with 
UnifiedGenotyper batch calling (with 93.4%, 97.6% overlap respectively). 
However, UnifiedGenotyper batch calling has 95.2% overlap with HyplotypeCaller while 
54.6% overlap with UnifiedGenotyper alone. The smaller proportion of overlap for 
UnifiedGenotyper also occurs when compared with Varscan (hg19 as reference) as shown 
in Figure 4.7. The raw SNPs were then filtered using ts_filter_level of 99.0, 
corresponding to sensitivity that would allow retrieve 99% of true variants from the 







Figure 4.8 Venn diagram of the number of SNPs called by HyplotypeCaller, 




 After variant calling, I detected 17,584 raw SNPs in total, but these were reduced 
to 10,451 total SNPs passing the filters that lie within the 2kb promoter regions of 472 
genes.  8,833 of the SNPs are rare (defined as MAF < 0.05) and 1,618 are common (with 
MAF >= 0.05), which averages 1.5 rare variants per promoter per individual.  An average 
of 60% of these rare variants are private, meaning that they were only observed in a 
single individual.  Table A.2 lists the number of rare, common, and private SNPs per 
gene, along with an estimate of the polymorphism rate (π) per gene. 
Validation with Sanger Sequencing 
 To verify the accuracy of the high throughput sequencing, I Sanger sequenced 
500bp segments of two genes, TRAF3IP3 and HSPA8. The sequenced region of 
TRAF3IP3 was chr1: 209929132 – 209929708, in which 2 rare SNPs and 4 common 
SNPs were observed in the 410 samples. All of these were included in 96 samples that 
were Sanger sequenced, and all were validated.  The sequenced region of HSPA8 was 
chr11:122932665 – 122933158, which contained 18 rare and 5 common SNPs in the 96 
sequenced samples, which were again verified by Sanger sequencing.  A handful of other 
individuals were nominally positive at some of the rare sites, but manual inspection of the 
traces revealed poor quality sequence toward the ends of the reads in those individuals 
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suggesting a false positive rate that in any case would be less than 0.5%. Five variants 
that were not present in the GATK analysis but were called by Sanger sequencing were 
all with low confidence, whereas all common variants were also validated by the Sanger 
sequencing. 
I also have whole genome genotypes either from Illumina Omni or CoreExome 
arrays, imputed onto 1000G with Impute2, for the majority of individuals.  99.8% 
concordance was observed.  These genotypes were thus used for common variant eQTL 
analysis, which will be described in detail elsewhere. 
Rare Variant Distribution Comparison 





Figure 4.9 Number of rare alleles in promoter regions for 410 samples from different 





As expected, the number of rare variants per individual varied by ethnicity.  
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Shown in Figure 4.9, on average, there were 233, 74, and 52 variants with MAF<5% in 
each of the African, Asian and Caucasian ancestry samples respectively, representing a 3-
fold excess in Africans relative to Asians, and 4-fold excess relative to Caucasians. The 
difference is highly significant (ANOVA, p = 3x10-263). An excess of rare variants in 
African ancestry samples compared to Asian and Caucasian ancestry samples was also 
observed in the independently analyzed whole genome sequence replication sample, 
where the number of rare variants per promoter of the 472 genes in African ancestry 
individuals was not statistically different from that observed in the CHDWB sample 
Africans, although almost twice as many variants were called per individual in the 
Caucasians.  [1] and [110] also report a 3-fold excess of rare variants genome-wide in the 
1000G genome sequence data, averaged over regulatory, coding and intergenic regions. 
 There was no significant difference of rare allele count between females and 
males, in all three ethnicities (data not shown; t-test p-values 0.54, 0.34, and 0.68 in 
Africans, Asians and Caucasians separately). 
2) eQTL genes vs non-eQTL genes 
 Common eQTL analysis were performed with PLINK using imputed microarray 
genotyping data and microarray expression data. The detailed information will be 
described in the next chapter. 207 genes out of 410 total genes have significant common 
eQTL. There was no significant difference of rare SNP numbers between genes with 








Figure 4.10 The rare allele count in genes with common eQTL SNPs versus genes 




3) disease related genes vs non-disease related genes 
 From Figure 4.11, the mean of rare allele count in genes with Metabochip SNPs 
inside the gene body or within the promoter regions was 19.11, while the mean of rare 
allele count in genes without Metabochip SNPs was 18.29. The difference was not 
significant (t-test P-value 0.10). Similarly, the mean rare allele count in genes with 
Immunochip SNPs inside the gene body or within the promoter regions was 19.03, while 
the mean of rare allele count in genes without Immunochip SNPs was 18.44 (t-test P-
value 0.17). The mean of rare allele count in genes with Metabochip SNPs or 
Immunochip SNPs inside the gene body or within the promoter regions was 19.12, while 
the mean of rare allele count in genes without Metabochip or Immunochip SNPs was 





Figure 4.11 The rare allele count in gene subsets with respect to Metabochip and 
Immunochip. A. genes with Metabochip SNPs versus genes without Metabochip SNPs. 
B: with Immunochip SNPs versus genes without Immunochip SNPs. C. in genes with 
Metabochip SNPs or Immunochip SNPs versus genes without Metabochip SNPs or 




4) upstream vs downstream 
 Within 1kb upstream region of TSS of 472 genes, there were 4,543 rare SNPs, 
compared with 4,290 rare SNPs within 1kb TSS downstream region of 472 genes (Figure 
4.12). These distributions of rare allele count were not significantly different between 







Figure 4.12 The distribution of rare allele counts in upstream (left) and downstream 
(right) of TSS for all 472 genes in all 410 samples. There is no difference between 








Figure 4.13 The distribution of the number of rare SNPs in each RegulomeDB class. 




 Figure 4.13 shows that the RegulomeDB scores don’t differ significantly between 
upstream region and downstream region. There are 5 genes that harbor the rare variants in 
RegulomeDB 1b and 1f classes. 432 genes harbor the rare variants in RegulomeDB 2a-2c 
classes. 264 genes have rare variants in RegulomeDB 3a and 3b classes. 461 genes have 
rare variants in RegulomeDB 4 class. In addition, 464 genes have rare variant which are 
in RegulomeDB classes 1 through 4, which are the classes with strong evidence that 
those regions encompass functional regulatory elements. So in total, more than 98% of 
those 472 genes have promoter proximal rare variants in regulatory sites. There is thus a 
lot of opportunity for rare variants to have regulatory functions. 
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Nucleotide Diversity Comparison 
1) Between promoter region and coding region 
The average nucleotide diversity 1kb upstream of TSS is highly correlated with 
that observed in the full 2kb promoter region (p=3.5x10-119, r2=0.68, Figure 4.14A), 
indicating that just the upstream region is a good proxy for the full promoter. Next I 
observed that there is also a significant association between nucleotide diversity in 
upstream promoter regions and in coding regions (slope=0.6, p=1.3x10-22, r2=0.19, Figure 
4.14B).  This indicates that upstream promoter regions have relatively lower sequence 
diversity than coding regions. However the high correlation is likely due to a combination 
of linkage disequilibrium affecting background purifying selection on function, and 
similar constraints on coding and regulatory regions. 
 
 
         
Figure 4.14 Linear regression fitting nucleotide diversity in upstream region on the 
full promoter (A), and on the coding region (B). Red dots in B represent the bottom 
25% genes, with negative relative promoter polymorphism compared to coding regions. 
Blue dots represent the top 25% genes with positive relative promoter polymorphism. 
 
 
Despite this high correlation, there are nevertheless genes that have more promoter 
polymorphism than expected, and genes with less, relative to the coding region. In order 




calculated the studentized residuals after regression of per-base nucleotide diversity (π) in 
upstream promoter regions on π in coding regions, generating a parameter I call “relative 
promoter polymorphism”. A residual of 0 means the gene has average level of promoter 
polymorphism. A positive value means the gene has more promoter polymorphism and 
negative value means less promoter polymorphism, with respect to the coding region of 
the same gene. 
Next, I compared the relative promoter polymorphism with the “residual variation 
intolerance scores” (RVIS) as reported by [92]. RVIS is a measure of intolerance to 
functional mutations, and is computed as the ratio of common missense or truncation 
variants (MAF>0.01) to all variants in a gene region. In coding regions, RVIS is highly 
significantly associated with functional measures such as whether a gene is known to 
harbor Mendelian mutations, and has been proposed as a means of scaling the likelihood 
that a rare or de novo coding variant causes disease. There is however no significant 
linear relationship between my relative promoter polymorphism measure and coding 
RVIS.  This implies that tolerance of functional variation in coding regions is not strongly 
correlated with levels of promoter polymorphism. 
2) Between gene subsets with disease related status 
 The genes with Immunochip SNPs show significantly higher nucleotide diversity 
in upstream regions, compared with the genes not harboring Immunochip SNPs (ANOVA 
p=0.036, Figure 4.15A). The genes harboring Metabochip SNPs also show higher 
nucleotide diversity in upstream regions in comparison with the genes without 





   
Figure 4.15 Comparison of nucleotide diversity in upstream region for genes with or 




 From the comparison of SNP calling by GATK and VarScan, the calling algorithm 
introduces considerably more bias in SNP detection than does read depth. Other 
researchers have reported similar results: O’Rawe et al [111] reported that different 
variant calling pipelines (including SOAP, BWA-GATK, BWA-SNVer, GNUMAP [112], 
and BWA-SAMtools) only had a 57.4% concordance rate. The reference template also 
causes a big difference in targeted sequencing alignment. As shown in Varscan, using the 
targeted region as template tends to call 4 folds more variants than using hg19 reference. 
When choosing the algorithms for calling the variants, decisions should be guided by the 
nature of the sequencing dataset and the specific questions being asked, and appropriate 
parameters need to be selected for each algorithm. For example, the whole genome 
reference such as hg19 is usually better than targeted sequence as reference, as using 
whole genome reference will get the best mapping position for a read to decrease the 
likelihood that reads are mapped to wrong places. 
            The sequence diversity of rare variants in promoter regions is very high in African 
ancestry samples compared to rare variants in Caucasian and Asian ancestry samples. It 




ancestries. The population bottleneck caused by the out-of-Africa migration may serve as 
an explanation of the lower diversity in Caucasian and Asian ancestry samples. The 
hypothesis has been raised [113, 114] that due to the out-of-Africa migration reducing the 
effective population size for modern humans, non-African populations tend to experience 
stronger genetic drift in addition to the founder effect leading to loss of diversity. In 
addition, adaptation to new environments possibly leads to some selection against 
common genotypes or selective sweeps. Further, in comparison with the finding of three 
times the number of rare variants in Africans than in Caucasians from 1000 Genomes, my 
result showed more enrichment of rare variants in Africans. That is possibly because the 
read depth is much higher in my sequencing data compared to 1000 Genomes project, 
leading to higher power to detect rare variants. Another explanation is that the filtering 
method VQSR after GATK variant calling is more stringent than what is used in 1000 
Genomes project, leading to calling of fewer rare variants found in Caucasians. 
The rare SNP count is not obviously different between different regions and 
classes of genes. The only comparison that showed a statistically significant difference 
was that the genes represented on either Metabochip SNPs or Immunochip SNPs have a 
slight tendency to harbor more rare variants. The significant association between 
nucleotide diversity of promoter region and coding region implies that the genes with 
evolutionary constraint on the coding region also show constraint on the promoter region. 
Petrovski et al [102] reported that the genes that are related to immune disease tend to be 
tolerant to more common functional mutations. My result supports their finding to the 
extent that the genes which are potentially related with metabolic disease or immune 
disease tend to have more highly polymorphic promoters.  However, the RVIS score is 
not likely to be a good measure of the intolerance of promoter regions to functional 
variation. Development of a promoter specific intolerance score will require 
incorporation of an estimate of which variants influence gene expression, which is the 




RARE REGULATORY VARIANTS ASSOCIATION  
WITH TRANSCRIPT ABUNDANCE 
 
Introduction 
 In recent years, whole exome sequencing has been used effectively to demonstrate 
that there is a burden of rare coding variants in individuals with a variety of neurological 
and developmental conditions [115-118].  Considering estimates that as many as 90% of 
disease associated common variants are regulatory rather than structural [37, 98-100], it 
is reasonable to assume that rare regulatory variants influencing the expression of causal 
genes might also be enriched in individuals with congenital abnormalities. Whole 
genome sequencing may address this issue, but will need to confront multiple comparison 
issues given the enormous size and complexity of regulatory sequences.  
 Gene expression, whose pattern and properties play a fundamental role in 
affecting the functions of genes, cells and also phenotypes [119], has attracted 
considerable attention. As an important intermediate phenotype between gene variants 
and phenotypic traits, gene expression is a key to uncovering the underlying genetic 
mechanisms responsible for variation for complex traits and diseases. While many studies 
have explored the association of genetic variants with gene expression traits, common 
eSNPs can only explain a medium proportion of gene expression variation [120], which 
implies the rare variants may also make a contribution. Whereas the genetic functions of 
rare variants in coding regions are well studied, association of regulatory rare variants 
with expression traits has yet to be described. Here I test for a burden of rare variants 
with gene expression itself, focusing on just the promoter regions of a targeted set of 




 Power issue is one the most important considerations in rare variant association 
tests. Previous studies have reported that at least 20,000 samples were needed to reach the 
enough power to perform rare variant association test [121, 122]. In this study, I utilized a 
novel pooled burden test to overcome the difficulties when using much fewer samples. As 
the promoter regions of each gene could be viewed as independent and only cis-acting 
variants were considered in this study, it is reasonable to view the promoter regions of 
each gene in each individual as independent measures. The overall test approach I used 
was to combine all the promoter regions across all individuals to enlarge the number of 
independent tests.  
 The burden test was designed to test whether rare variants are enriched in the 
promoters of genes that are at the extreme of transcript abundance. Robust association 
tests were also performed by evaluating a series of rare variant association tests, 
conditioning on common-eSNPs, and regulatory features. The results of this study 
showed an overall signature of association enrichment across subsets of genes, as well as 
provided an estimate the magnitude of rare variant effects. This study provides evidence 
for rare variant association with transcript abundance, strongly supporting a possible 
general and pervasive contribution of cis-regulatory effects of rare variants as a source of 
genetic variance for rare clinical traits. 
Materials and Methods 
Samples 
 The 410 samples were from the Atlanta CHDWB cohort under approval of the 
Emory University and Georgia Tech IRBs for genetic studies. The 410 samples were 
comprised of 274 females and 136 males. The samples were a mixture of 297 Caucasians, 
95 Africans and 18 Asians. The age at entry into the program and initial sampling of 
blood spanned from 19 to 83 with a mean of 50 and standard deviation of 10.6.  
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DNA  Re-sequencing and Variant Calling 
 The targeted capture sequencing of promoter regions was described in detail in 
the previous chapter and is briefly summarized here.  Whole blood was extracted from 
410 samples and DNA was extracted by QIAGEN FlexiGene DNA Kit. 472 genes were 
selected (list and criteria as in Chapter 4). The major transcript start sites (TSS) were 
obtained from UCSC Genome Browser. A capture array was designed using Illumina 
design studio to pull down 1kb upstream and 1kb downstream of the major TSS for each 
of the 472 genes. Sequence capture libraries were generated and pooled using Illumina 
TruSeq DNA Sample Preparation Kits and TruSeq Custom Enrichment Kits. Sequencing 
was performed on an Illumina HiSeq 2500 with the assistance of Ms. Shweta Biliya in Dr. 
Fredrik Vannberg’s group at Georgia Tech, providing an average coverage of 600 X. 
The sequences were aligned by BWA and variants were called using the GATK 
UnifiedGenotyper in one batch for all 410 samples. Variants were defined as rare in this 
study if the minor allele frequency (MAF) was less than 0.05 in the 410 samples. After 
quality filtering using VQSR, there was a total of 10,451 SNPs, including 1,618 common 
SNPs and 8,833 rare SNPs. 
Gene Expression Profiling 
Transcript abundance measures were generated in two batches using Illumina-
HT12 human gene expression arrays. RNA was prepared from whole blood samples 
collected and stored in Tempus tubes (Life Technologies), following manufacturer-
recommended protocols, and quality was confirmed using an Agilent Bioanalyzer such 
that all samples had RIN numbers greater than 8. The first batch of samples was 
processed for hybridization and bead intensity extraction by ExpressionAnalysis 
(Durham, NC) and the second by HudsonAlpha (Huntsville, AL). The raw data is 
available at the Gene Expression Omnibus (GEO) as accession GSE61672, but additional 
data processing steps were employed for this study to account for batch effects that 
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skewed the rare variant association statistics. 
Gene Expression Normalization 
The objective of this study was to evaluate whether or not there is enrichment for 
rare variants at the extremes of the transcript abundance distribution across a population.  
The question is not whether genes that have high or low abundance tend to have more 
rare variants. It is whether individuals with extreme abundance of single genes have an 
excess of rare variants in those genes. If we could measure the abundance of a single 
transcript in 100,000 people, we may expect that promoter regions of genes in the lower 
and/or upper percentiles of the distribution tend to have more rare variants than genes in 
the middle of the distribution.  Since we did not have the resources to perform such a 
comparison, instead I reasoned that we could pool the results of almost 500 genes, each 
measured in more than 400 people, and evaluate whether there is signal in the tails of the 
distributions of all of the genes considered jointly.  The signal for any one gene would not 
likely be significant, but with 472 genes there are over 200,000 gene expression 
measures, providing power. 
For this strategy to be informative, it is essential that there is no relationship 
between polymorphism levels in an individual, and the tendency of individuals to have 
more genes with extreme expression.  For example, if a subset of genes tend to be more 
highly expressed in African Americans, then those genes would be toward the upper tail 
and they would tend to have more polymorphic variants, and hence a regression of rare 
variant count against percentile of gene expression would have a positive slope.  Vice 
versa for genes that tend to have lower expression in the group with higher 
polymorphism, while the combination of both biases would tend to generate concave 
“smile” plots.  It is also relevant to note that biases other than ethnicity could result in a 
significant relationship, including technical batch effects. In the presence of such biases, 
permutation of the genotype and gene expression matrices across individuals would result 
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in significant linear or quadratic terms in our test statistic just as observed for the real 
data.  Actually, such effects were observed in our initial evaluation of the raw data, which 
led us to adopt the normalization strategy outlined here. 
Raw expression data in the form of average bead intensities from the Illumina 
Genome Studio were first transformed to log2 values, and then processed with the 
Supervised Normalization of Microarrays (SNM) [123] algorithm in R.  I fit Age as the 
biological variable, and removed effects of Batch and Ethnicity by including these as 
adjustment variables with the rm=True option.  Individual effects were accounted for as 
the intensity-dependent variable, resulting in overall gene expression profiles with the 








Figure 5.1 Distribution of raw log2 transformed expression (top), and SNM 






Figure 5.1 shows the distribution of raw log2 transformed expression and SNM 
normalized expression. The raw expressions have a strong batch effect which is adjusted 
well by SNM normalization. After performing variance component analysis (Figure 5.2), 
batch effect reduced from 74.6% to 0, making 90.8% of the variance explained by 




      
Figure 5.2 Variance component analysis of raw log2 transformed expression (left), 




I next extracted the 472 genes for which we have promoter genotypes, and 
averaged the estimates for 177 genes that are represented by 2 or more probes in the 
Illumina-HT12 arrays.  In order to combine the genes, I next sought to convert each gene 
expression distribution to the same scale, namely to z-scores, which are standard normal 
distributions with a mean of 0 and standard deviation of 1.  To ensure that there was no 
overall batch effect on the variances (namely, that individuals from one batch are not, for 
technical reasons, more likely to have extreme values), I fit the z-scores by batch and 
combined them. 
Rare Variant Burden test 
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 In order to evaluate whether there was a relationship between transcript 
abundance and number of rare variants in the promoter, each gene was placed in one of 
82 equal-sized bins of five individuals based on the rank of the batch-adjusted z-scores.  
For each gene separately, the lowest 5 individuals are in bin 1, the next lowest 5 are bin 2, 
and so forth until the top 5 are bin 82.  The number of rare variants, defined as a variant 
with a MAF < 0.05, in the promoter region of each gene in each bin was summed, and 
subsequently these values were summed across all 472 genes.  The plots in Figure 5.3 
show the strategy obtaining the sum total of rare variants in 472 promoters in bins of 5 
individuals, starting with bin 1 at the left and ending with bin 82 at the right.  I then 
evaluated deviation of the distribution from the null hypothesis of no relationship by 
fitting a quadratic model where the linear term captures bias toward enrichment for either 












 The significance values of the two terms were observed to be very similar to the 
empirical p-values obtained by permuting the sum counts against the bin number.  
However, a more robust permutation is to shuffle the genotype and gene expression 
vectors, keeping the full vector of promoter counts within each individual, and the full 
vector of expression ranks, constant so as to preserve any biological covariance.  With the 
appropriately normalized gene expression data, such permutations generally resulted in 
flat regressions of allele count on expression bin, with non-significant linear and 
quadratic terms.  I then evaluated the significance of the actual data by documenting how 
many permutations out of 10,000 have a more significant overall model fit, which turns 
out to be just a few cases, strengthening support for the inference (i) that the 
normalization has removed systematic biases, and (ii) that there is a true burden of rare 
variants at either extreme of the transcript distribution, averaging across 472 transcripts. 
A further adjustment was made to account for unequal total read counts among 
individuals or in specific genes. In particular, the up to 4-fold difference in rare variant 
counts between African and Caucasian ancestry individuals could bias the analysis if 
certain genes are more variably expressed between ethnicities; and I noticed that not 
infrequently, individuals harbored “extreme genotypes” with three or more private or rare 
polymorphisms in the same gene.  For the analyses involving mixed races, I thus 
performed a haplotype burden analysis by collapsing all multi-SNP promoters down to a 
count of 1, instead of the actual number of rare variants. This should be conservative 
since it will tend to underestimate the contributions of two or more variants in a single 
promoter.  Application of this haplotype burden test to just the Caucasian data reduced 
the significance of the quadratic fit in smile plots, but the general trend remained the 
same as with the full SNP count data. 
A variety of biological factors could mask the effect of rare variants by 
increasing the variance of gene expression. Two obvious effects are the contribution of 
common eQTL, which will tend to cause individuals with the less active polymorphism 
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to be in lower expression bins, and trans-acting sources of gene expression covariance.  
Since peripheral blood preserved in Tempus tubes is a complex mixture of leukocytes 
(residual red blood cell and platelet gene expression is not thought to contribute strongly 
to observed transcript abundance), an obvious source of covariance is cell counts: 
individuals with low T cell counts for example may tend to have coordinate low 
abundance of thousands of transcripts that are enriched in T cells.  Cell counts explain a 
little over a third of the transcriptional variance in the dataset. This is actually half the 
amount explained by seven empirically determined common axes of covariance that 
likely reflect a mixture of contributions of cell counts and coordinate gene regulation for 
example by interferon or other systemic factors.  These seven axes are defined by the first 
principal component of the expression of 10 “blood informative transcripts (BIT)” [124] 
per axis, where the BIT have been defined by comparison of multiple blood gene 
expression datasets.  Fitting PC1 to the 5 or 100 most correlated transcripts in each axis 
results in almost identical scores. 
Simple linear regression was used to fit either eQTL or co-expression Axes or 
both together.  For the eQTL adjustment, I first performed whole genome cis-eQTL 
analysis on the full CHDWB dataset and identified significant eQTL located within 5kb 
of the TSS or in the gene body for 207 of the 472 genes at p<10-4, observing more than 
70% overlap with the Blood eQTL browser variants derived from meta-analysis of over 
5,000 samples.  For 112 genes, multiple additional cis-eQTL were observed conditioned 
on the primary eQTL.  With the assistance of another graduate student in my lab, Biao 
Zeng, stepwise linear regression was useed to fit these empirical eQTL in our dataset, 
also including Age and Sex as covariates in the model (although neither age nor sex 
account for more than a few percent of the variance of any of the 472 genes).  The 
residuals from the eQTL fit were then ranked and placed in bins for the burden test.  For 
the Axis adjustment, I computed the 7 PC1 scores from the full SNM normalized gene 
expression matrix, and then identified which axis was most strongly correlated with the 
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expression of each gene (448 were influenced by an axis at p<10-4).  Univariate linear 
regression was then used to fit the relevant axis for each gene, and again the residuals 
were taken forward to the adjusted burden test.  For the joint fitting of eQTL and Axis 
scores, I performed the regressions in a sequential manner. 
Two other versions of the analysis were performed to confirm the robustness of 
the core result.  First, I performed quantile normalization of the log2 transformed data 
[125].  This procedure results in identical overall transcript abundance distributions by 
ranking gene expression within individuals and assigning each rank the mean value of 
transcript abundance for that rank.  It does not however remove systematic sources of 
variance at the level of individual genes, such as batch or ethnicity effects.  Second, 
rather than ranking each gene separately, I also performed an overall percentile method 
where all of the z-scores of the 472 genes were combined and assigned to 82 bins of 
2,360 transcripts.  This analysis allows the same gene to be present in the same bin in 
multiple individuals, so does not assume that each gene is approximately normally 
distributed.  Clusters of individuals who share a rare variant and extreme expression 
might consequently be further enriched toward the extreme.   
Partitioning the Sources of Rare Variant Burden on Gene Expression 
            As described in the results section, several potential modifiers of the rare variant 
contribution were evaluated by dividing the total Caucasian dataset into subsets and 
comparing the model fit.  For example, to evaluate whether suspected regulatory sites are 
more likely to harbor rare variants, I downloaded the RegulomeDB assignments for each 
SNP and contrasted sites with scores in the ranges 1-4 (likely regulatory) or 5-7 (weak or 
no evidence for regulatory potential).  Similar analyses reported in Table 5.1 contrast 
SNPs upstream and downstream of the TSS; SNPs in genes in the upper of lower halves 
of the overall average transcript abundance spectrum; SNPs in genes in the upper or 
lower halves of the average promoter polymorphism distribution; SNPs in genes with or 
89 
 
without common eQTL; and SNPs in genes represented on the Metabochip, Immunochip, 
or neither.  
Replication Dataset 
            In order to replicate the rare variant enrichment on a completely independent 
dataset generated with different gene expression and genotyping technologies, Professor 
David Goldstein provided a small cohort of 75 individuals with whole genome sequence 
and whole blood RNA-Seq at the Duke Center for Human Genome Variation. Most of 
these individuals are from a Schizophrenia study.  Permission to perform genetic analysis 
was obtained under IRB approval of Duke University, affirmed by the Georgia Tech 
IRB.  Analysis of the principal components of the genotypes indicated that the sample 
includes approximately 49 Africans and 26 European Ancestry individuals.  
            Whole genome sequences were obtained on Illumina HiSeq2000 automated DNA 
sequencers and genotypes were called individually with the GATK algorithm.  RNA-Seq 
of whole blood preserved in Tempus tubes was performed also by paired end 100bp 
sequencing on the Illumina platform.  Raw read counts were log2 transformed, and mean 
centered, and linear regression fitting each of the 7 axes of variation (represented by PC1 
of the blood informative transcripts) as well as the overall PC1 of gene expression 
variation (which is correlated with genetically determined ancestry).  Subsequently, I 
assigned the rank of each gene in each individual, and performed quadratic regression of 
the total rare allele counts (MAF<0.05) for each of 75 ranks.  That is, rather than pooling 
5 individuals per bin, the analysis was essentially on bin sizes of 1, necessitated by the 
small sample of individuals.  
Experimental validation of SNP effects by genome editing 
            I chose four SNPs for experimental validation by CRISPR/Cas9 mediated genome 
editing.  Two (rs in TDP1 and rs in COMMD4) were associated with loss of gene 
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expression and two (rs in DHX29 and rs in UQCC) with gain of gene expression in the 
CHDWB targeted sequencing analysis.  For each gene Dr Idowu Akinsanmi in the 
Gibson lab and Dr Ciaran Lee in the laboratory of Professor Gang Bao generated 11 or 12 
independent approximately 10-cell K562 clones targeted by guide RNAs as follows (need 
paragraph from Idy).  Although K562 cells are erythroleukemic, rather than lymphoid or 
myeloid [126], since the variants are promoter proximal, we reasoned that they may have 
effects generally on transcript abundance and this cell line is well established for CRISPR 
experiments. 
            After confirming disruption of the relevant SNP by the T7E1 assay [127], 8 clones 
for each of the 4 genes with average heterozygosity between 16% and 23% were 
selected.  Assuming a 2-fold modification of transcript abundance in one fifth of the cells 
affected by the CRISPR, we require a sensitive gene expression assay capable of 
detecting a 20% modulation of gene expression.  Droplet PCR is a new quantitative PCR 
approach that does not rely on thresholds of product generation in real time, but rather 
consists of 10,000 dilute droplets of RNA [128].  Quantitative transcript abundance 
estimation is generated by scaling the counts of droplets (typically between 500 and 1000 
out of 10,000 for the transcripts considered here) to the number of positive droplets for 
two control genes measured in aliquots of the same RNA sample.  HPRT was a common 
housekeeping gene control, while UQCC was used as the second control for TDP2 and 
DHX29, and TDP2 as the second control for UQCC and COMMD4 disrupted clones. 
Results 
The overall burden test on the full cohort (Figure 5.4A) showed that the rare 
variants were enriched in both increased and decreased gene expression (model R2 = 
0.19, p=0.0003, permutation p=0.0002). In addition, the enrichment of rare variants in 
decreased gene expression is more obvious than the enrichment in increased gene 
expression. The full cohort was composed of 297 Caucasians, 18 East Asians, and 95 
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Africans. Because of the limitation of imputation quality, after fitting common variants 
the cohort included 384 individuals, composed of 279 Caucasian, 18 East Asian, and 87 
African American individuals. As African Americans have differential expression for one 
third of the genes, and almost three times more rare variant counts than Caucasians in the 
promoter regions (consistent with HapMap estimates), I also considered each of the two 
larger population groups separately. In addition, adjusting for covariates which are known 
to affect gene expression improves the rare variant test significance. The covariates 
include common eQTLs and principle component scores for 7 common axes of peripheral 
blood gene expression covariance. These 7 axes collectively explain 26% of the total 
expression variance of the 472 genes. Fitting those two covariates improve the model R2 
from 0.05 to 0.17, p=0.07 to 0.0003 for Caucasians (Figure 5.4B). That is the further 
evidence that the regression models truly capture enrichment for rare variants. Africans 
separate test (Figure 5.4C) also shows the same trend with enrichment of rare variants at 
the two extremes of gene expression. The less significance in Africans may be due to 
smaller samples size compared to Caucasians. It was verified by randomly selecting the 
same number of Caucasians as Africans to perform the test. Besides rare variant count, I 
also used rare haplotype counts as some individuals carry more than one rare SNP. Both 
show the same trend of enrichment in high and low gene expression. I also applied 
different normalization methods for gene expression, including quantile normalization 
and an approach that firstly pooled z-score for all the gene expression measures together 
and then assigned bins. Both normalization approaches show the enrichment of rare 
variants at two extremes of gene expression, meaning the enrichment test is robust with 
different normalization methods (Figure 5.5). In addition, grouping gene expression into 
41 bins with 10 individuals in each bin (Figure 5.6A) or setting the rare variants as MAF 
less than 0.01 (Figure 5.6B) also shows significant enrichment of rare variants at the two 





Figure 5.4 The rare variant burden in sorted expression (SNM normalized) bins. A. 
410 samples, no adjustment B. 279 Caucasian Americans, after fitting SNM expression 
levels by significant common eQTLs and 7 blood transcript axes. C. 87 African 
Americans, after fitting SNM expression levels by significant common eQTLs and 7 







          
Figure 5.5 The rare variant burden using different normalization method of gene 
expression. A. The rare variant burden in sorted expression (QNM normalized) bins for 
410 samples. (R2=0.16, p-value=0.002) B. The rare variant burden in expression 




                
 
Figure 5.6. The rare variant burden using different bin sizes and different minor 
allele frequency cutoff. A. separating gene expression to 41 bins with 10 individuals in 






 I also asked if the rare variant enrichment was due to certain subsets of genes or 
gene regions. The result was shown in Table 5.1 and Figure 5.7. I first categorized genes 
by RegulomeDB classifications. Lower classification of RegulomeDB (classes 1 to 4) 
means higher confidence that the variants lie within features such as DNAse 
Hypersensitive Sites or Transcription Factor Binding Sites. It showed that the rare 
variants which lie in class 1 to 4 of RegulomeDB were more enriched at the extremes 
than the variants in classes 5 to 7 (p=0.002 versus 0.08). Second, the variants were 
grouped into two subsets according to if they are in upstream or downstream of TSS. It 
showed that the rare variants in the downstream of TSS were more enriched at the 
extremes of gene expression in comparison of upstream (p=0.00067 vs 0.094). Third, I 
also asked if high or low abundance transcripts and if high or low polymorphic genes 
tend to show different patterns of rare variant enrichment. Result showed that the 
enrichment of rare variants occur in both high abundance transcripts and low abundance 
transcripts (p=0.0062, p=0.0009 separately). Similar result showed that the enrichment 




Table 5.1 Summary of quadratic model coefficients in different gene subsets. Model significance: * 0.001<p<0.05; ** 0.0001 




First Set Second Set 
Linear p Quad p Model R2 Linear p Quad p Model R2 
Caucasian vs African 0.029 0.00046 0.17** 0.16 0.046 0.068* 
RegulomeDB class 1-4 vs 5-7 0.16 0.0013 0.13* 0.08 0.15 0.055 
Upstream vs Downstream 0.12 0.12 0.051 0.12 0.00042 0.15** 
Low vs High Expression 0.00079 0.079 0.14** 0.35 0.0023 0.11* 
Low vs High Polymorphism 0.50 0.12 0.032 0.032 0.0018 0.14** 
with common eQTL vs not 0.027 0.0012 0.15** 0.33 0.058 0.049 
with Metabochip vs not 0.81 0.45 0.007 0.0057 0.000046 0.23*** 







Figure 5.7 The rare variant burden in sorted expression (SNM normalized) bins for 279 Caucasians in different subsets. A, B. 
rare variants in regulomeDB classes 1-4, and 5-7 respectively C, D. rare variants in upstream and downstream of TSS E, F. genes with 
high and low transcript abundance G-H genes with low and high polymorphic levels. 
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Next, I also investigated the enrichment of rare variants with respect to gene 
function. It showed that rare variants were more enriched in the genes with common 
eQTLs (Figure 5.8A, p=0.0006) compared to the genes without eQTLs (p=0.11). Another 
remarkable finding was that rare variants tend to show more significant enrichment in 
genes that do not harbor SNPs  in Metabochip or Immunochip. (p=9×10-6, Figure 5.8B, 
versus 0.73 for metabolic disease-related genes, and p=0.0047 versus 0.11 for immune-
disease-related genes). This result might be explained by relaxation of purifying selection 




    
Figure 5.8 The rare variant burden in sorted expression (SNM normalized) bins for 
279 Caucasians in different gene sets with respect to gene function. A. in genes with 





 The effect size calculation was based on the difference between the average 
expression levels of the samples with rare variants and the average expression levels of 
the rest samples in each SNP position (Figure 5.9A). When simulate with assigning effect 
size as gamma(1.5, 0.12) distributed and expression levels as normally distributed for 




5.9C) comparable to the true results. However the simulated distribution has smaller 
variance when compared to the empirical effect size (Figure 5.9B). This is likely due to 
the absence of technical noise in the simulated data. Accordingly, the observed effect 
sizes have only a modestly greater variance than those estimated in 100 random 






      
 
               
 
Figure 5.9 Effect size analysis. A. The distribution of absolute effect size. B. The 
distribution comparison of rare SNP effect size in CHDWB Caucasians and simulation. 
C. The rare variant burden with simulated effect size. D. The distribution comparison of 











  I performed a replication test with 75 whole genome sequencing and 
corresponding whole blood RNA sequencing. When using the same 472 genes, the rare 
variants showed a significant enrichment at the extremes of gene expression (p=0.008, 
Figure 5.10A), in which the smaller p-value compared to 410 samples may be caused by 
smaller sample size. However, when enlarging the number of genes to 5000 genes and 
also adjusting the axes of variation, the results showed very significant enrichment of rare 




     
Figure 5.10 The rare variant association test with replicates. A. The rare variant 
burden in sorted expression (SNM normalized) bins with 75 individuals and 472 genes. 
B. The rare variant burden in sorted expression (SNM normalized) bins with 75 




In order to experimentally validate rare variant regulatory effects predicted from 
the statistical analysis, we used CRISPR/Cas9 to mutagenize four sites that had estimated 
effect sizes greater than 2.5 standard deviation units, in K562 erythroleukemia cells.  Five 
individual clones were grown for each disruption and cleavage was confirmed using the 
T7E1 assay indicating 16 to 23% average heterozygosity.  Quantitative RT-PCR 




expression (in genes UQCC and TDP2), resulted in reduced transcript abundance, as did 
disruption of one of the two sites associated with increased expression (in genes 
COMMD4 and DHX29, Figure 5.11).  Since this protocol causes small deletions rather 
than targeted replacement of polymorphisms, it is possible that the disruption removes a 
binding site for an activator in each case, leading to loss of gene expression whereas the 








Figure 5.11 CRISPR / Cas9 mutagenesis validation of rare SNP regulatory effects. 
A. All 5 clones with disruptions in UQCC reduced expression almost by half. B. 3 clones 
with disruptions in COMMD4 weakly increased the expression while 1 clone greatly 
increased the expression. C. 4 clones with disruptions in TDP2 reduced expression to 








 Whereas many studies working on gene expression regulation focus on common 
variants and rare coding variants, this study presents an analysis of rare variants in gene 
promoter regions with 410 samples. While it has been shown that large samples sizes are 
needed to detect rare variant association with enough power, here I use a novel burden 
test to perform the association test by considering each promoter region as independent 
and summing effects over all the genes. This method has shown the potential of using 
burden test as a method of detecting rare regulatory variants. It also provides candidate 
rare variants significantly associated with gene expression that can be tested in further 
gene-based analysis. Different gene subset regions and gene functions were analyzed 
which provides insight into the sources of the rare variant effects. These demonstrate that 
the position relative to the TSS, RegulomeDB classes that significantly associated rare 
variants belong to, and common eQTL and disease relatedness features, all influence 
whether genes are likely to harbor rare regulatory variant effects. This implies that further 
studies in different tissues and larger samples may pinpoint the sources of rare regulatory 
variants that may also impact gene expression. This study also demonstrates the good 
potential of CRISPR as a screening approach to validate rare regulatory variants that 
would affect gene expression.  
 Gene expression, whose levels could affect cellular functions and cellular states 
[129, 130], is an important intermediate phenotype between genotype and disease status. 
The extreme expression of genes may lead to abnormal phenotypes and even lead to 
diseases [131]. Many common SNPs have been found to be associated with gene 
expression levels [132-134]. Those common eSNPs would affect the average level of 
disease risks for the individual groups. For example, the individual groups carrying 
common risk alleles which increase or decrease the gene expression levels may in 
aggregate have higher disease risk than the groups which don’t carry risk alleles. In 
comparison with the overall effect of common eSNPs, the rare eSNPs in regulatory 
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regions will influence only less than 5% individuals who carry the risk alleles but may 
push their expression to extreme levels that lead to the change of their health status.  
 People may argue that rare variants do not deserve much attention because they 
only exist in a few numbers of individuals and also is likely to be selected against. 
However, Keinan et al [107] have stated that human population is recently under 
explosive growth, which is expanding by more than three orders of magnitude over 400 
generations. This explosive population growth will contribute a larger number of rare 
variants and is likely to increase the individual genetic burden of complex disease risk. 
My result has shown that the rare variants tend to affect gene expression with a similar 
magnitude as common eSNPs. Considering the expanding number of rare variants and 
the three to four fold greater numbers of rare variants than common variants, the potential 
contribution cannot be ignored. In addition, rare coding variants which may directly 
cause change of protein structure and function tend to have strong effects on fitness, 
which would be filtered out by evolution. In contrast, rare eQTLs could have more easily 
escaped purifying selection. So exome sequencing based studies of rare coding variants is 
not sufficient and focus should shift to rare regulatory variants. 
 This study has limitations in some aspects and could be developed in further 
analysis with more accessible resources and funding. One of the limitations is that this 
study only focused on 2 kb regions in the vicinity of TSS. Although enrichment of cis-
eSNPs were found within the regions of 1kb each side of TSS [46, 135], a large number 
of cis-eSNPs are located in more distal regions. This matches with the knowledge that 
many regions with regulatory functions such as DNase hypersensitive sites and 
transcription factor binding sites lie in distal positions relative to TSS [136, 137]. 
Expanding the study regions to tens or hundreds upstream of TSS will enable discovery 
of a more comprehensive list of rare variants that affect gene expression.  
 Here the tests were based on gene sequencing and transcript profiling in 
peripheral blood. It can be expected that if the test could be applied to single cell or tissue 
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types, it will reduce the noises caused by variable environments and cell counts. 
Especially, if the test could be implemented in cell or tissue types that are directly 
relevant to certain diseases, such as cardiac cells for coronary heart disease, it will 
provide more information about the rare variants effect on disease-related gene 
expression. To validate the rare variants effect on gene expression, more experimental 
validations are required such as experiments on knockout/knockdown mouse models. To 
further investigate whether there is similar effect of rare variants in promoter-proximal 
regions on diseases, the approaches applied here are required to implement on individuals 
who have congenital disorders. 
 The most important implication of this study is that the potential contribution of 
de novo and very rare variants to congenital disease cannot be ignored.  Currently whole 
exome sequencing is demonstrating that there is a burden of rare variants in relevant 
subsets of genes in children born with developmental disorders and neurological 
conditions [138].  However, by no means all cases are explained by exome sequencing.  I 
propose that rare regulatory variants that either greatly reduce or overexpress the gene 






 This dissertation reveals the association between genetic variants and phenotypes 
in overall. Chapter 2 utilizes the common genetic variants recorded in GWAS database to 
calculate the polygenic risk score for 3 common diseases and 3 quantitative phenotypes. 
The result shows that even in a small cohort, polygenic score could explain 5% variation 
of disease risk and quantitative phenotypes, which is comparable to other studies. Chapter 
3 is GWAS analysis on TNF-α and BMI/CRP with imputed genotypes, by participating in 
GWAS replication and meta-GWA study. The result reveals a replication of the top few 
SNPs being discovered as the most significant variants associated with TNF-α in the 
discovery phase. In addition, it shows that the effect size and effect direction in 
longitudinal model matches with the baseline model. The study also provided candidate 
variants to a meta BMI/CRP study throughout the genome. Chapter 4 makes use of the 
targeted resequencing to make a population genetics comparison focused on rare variants 
in promoter regions. It reveals that the rare variants in promoter regions in Africans are 3 
times more than in Caucasians and 2 times more than Asians. Chapter 5 investigates the 
association between rare variants in promoter regions and gene expression levels. A 
significant enrichment of rare variants for both increased and decreased gene expression 
was observed in the study.  
 The studies were based on small cohorts – approximately 400 samples in 
CHDWB. The small samples would limit the power to detect the significant signals in 
genomic association studies. Spencer et al [139] show that thousands and more samples 
are needed to reach enough power to detect common variants with medium effect sizes in 
GWAS, whereas tens of thousands of samples are needed to detect common variants with 
small effect sizes in GWAS. Furthermore, for variants with smaller minor allele 
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frequency, much more samples compared to common variants are required to detect the 
associated SNPs (Figure 6.1). Their simulation study was based on single SNP analysis. 
More powerful statistical methods such as SKAT [53], C-alpha test [52] etc have been 









Figure 6.1 Power for Common versus Rare alleles based on case-control studies 
simulated in Caucasian population based on CEU HapMap panel. Power is shown as 
solid lines and coverage is represented as dotted lines with y-axis as the value. Increasing 
sample sizes are shown in x-axis. From left to right plots, effect sizes are increasing from 







The rare variant association test in this dissertation was based on expression levels 
measured in healthy individuals. It would also be interesting to detect how the rare 
variants associate with disease status if a case control cohort were available. A trio study 
comprised of children with diseases and their parents with or without diseases could also 
be a powerful experimental design for the discovery of genetic factors including rare 





Figure 6.2 Variation of gene expression in different specimen groups for 45 samples. 
Ranks are based on 3,826 microarray measured genes. DLCL, diffuse large B-cell 
lymphomas. CLL, chronic lymphocytic leukemia. WB, whole blood. PBMC, peripheral 




 The genetic information, traits and expression levels were all extracted from 
whole blood from the samples. There are several cell types such as lymphocytes, 
neutrophils, monocytes in whole blood. Each cell type may harbor its own expression 
characteristic and different genetic association pattern. Studies based on whole blood 
tends to overlook the underlying patterns in different cell types. Importantly, [140] has 
shown that gene expression variation in the whole blood of healthy samples is smaller 
than the variation observed from samples with bacterial infection, and is much smaller 
than that seen in certain constituent cell types (Figure 6.2). It would be interesting if the 
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study could be performed on isolated cell types, or specific types of stimulated cells.  
 Experimental validation is an important approach to validate the rare variant 
association. The CRISPR/Cas9 results performed in our lab have validated 3 of 4 rare 
variants with large effect sizes, at least with respect to the requirement for the 
transcription factor binding site that is affected by the rare SNP. The ideal situation would 
be that all rare variants with large or medium effect sizes could be validated by 
CRISPR/Cas9 assays. Future work may evaluate whether predictions from evolutionary 
or ENCODE data can help to narrow down causal variants in LD blocks..  
 The association between genetic variants and gene expression or clinical traits 
will shed light on genetic association with diseases, in consideration of how aberrant gene 
expression levels lead to abnormal phenotypes and how clinical traits imply the status of 
health. It helps understand the molecular causes of diseases and identifies genetic 
contribution to variability in persons’ response to treatments.  Each person has a unique 
genome. Thus the information on personal genome and personal genetic variants based 
on the knowledge of genetic variant association will result in personalized medicine 
[141], where genetic information together with clinical information could be used to 
predict health risk. When a certain disease is diagnosed, personal treatment could be 
advised based on the patient’s genetic information, using methods such as that developed 




SUPPLEMENTARY TABLES FOR CHAPTER 4 
  
Table A.1 Read depth summary for 2kb promoter regions of 472 genes 
 
GENE AVERAGE  
READ DEPTH 
PROPORTION 
 >= 20X 
PROPORTION  
>= 100X 






ABCC5 967.61 0.89 0.81 LMAN2L 640.11 1 0.90 
ABHD10 232.04 1 0.54 LMNA 374.88 0.97 0.84 
ABHD8 342.62 0.85 0.73 LONP2 613.94 0.97 0.94 
ACAA2 648.05 0.95 0.88 LRPPRC 202.78 0.86 0.54 
ACADM 531.89 0.92 0.77 LRRC25 1202.00 1 0.98 
ACER3 591.86 0.86 0.62 LRRCC1 700.69 0.97 0.93 
ACOX1 732.98 0.99 0.96 LTN1 522.29 0.68 0.59 
ACP2 919.33 1 0.94 M6PR 942.01 1 1 
ACTR10 529.78 0.99 0.96 MAD2L1BP 614.31 0.97 0.81 
ACTR6 800.19 0.97 0.83 MAF1 583.77 0.70 0.56 
ADCK3 791.69 0.92 0.84 MAGEH1 877.61 1 1 
ADK 615.06 0.69 0.56 MAN2A2 879.03 1 0.98 
ADPGK 896.71 0.91 0.89 MAPK1IP1L 612.44 0.90 0.84 
ADRM1 493.36 0.76 0.63 MAU2 790.05 0.96 0.90 
ADSS 659.47 0.85 0.73 MBNL1 857.20 0.96 0.94 
AHSA2 457.19 0.85 0.71 MBNL2 853.06 1 1 
AKR7A3 821.00 0.94 0.91 MED16 594.32 0.93 0.74 
ALDH16A1 760.05 1 0.97 MED22 467.59 0.88 0.75 
ALDH2 794.47 0.85 0.79 MEFV 811.08 0.94 0.85 
ALDH3B1 923.90 1 1 MFN2 802.88 0.89 0.76 
ALKBH1 690.88 0.84 0.73 MGST3 1003.18 0.98 0.95 
ALPL 696.66 0.93 0.84 MKI67IP 571.78 0.99 0.97 
ALPP 740.51 1 0.82 MOBKL2C 378.27 0.90 0.70 
ALS2 815.91 0.92 0.90 MPHOSPH10 679.22 1 1 
ANXA11 695.83 0.94 0.91 MPL 1216.80 1 0.98 
AOAH 945.49 1 1 MR1 783.25 1 1 
AP1G2 621.99 1 0.88 MRPL17 1000.30 1 0.87 
AP1S1 636.69 0.97 0.86 MRPL34 806.25 1 0.94 
APOL3 696.60 1 1 MRPL43 1159.66 1 0.99 
ARAF 425.30 0.97 0.93 MRPL52 859.84 0.87 0.72 
ARGLU1 523.46 0.82 0.75 MRPL53 734.97 1 1 
ARID5B 430.77 0.99 0.90 MRPS21 962.16 0.95 0.88 
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ARL16 565.28 0.92 0.73 MSH6 382.81 0.93 0.80 
ARPP19 564.50 0.95 0.80 MSI2 319.81 0.74 0.65 
ASNSD1 944.69 1 1 MSRA 550.34 0.97 0.92 
ASXL2 627.28 0.92 0.77 MTMR3 564.05 0.78 0.59 
ATG4A 568.33 1 0.99 MYC 732.29 0.92 0.81 
ATMIN 602.45 0.88 0.79 NAA10 865.92 0.83 0.71 
ATP13A1 342.72 0.80 0.49 NDUFB10 740.15 0.89 0.81 
ATP5J2 819.30 0.86 0.77 NEDD8 627.31 0.94 0.87 
ATP5S 597.54 0.90 0.84 NEDD9 925.46 1 1 
ATPIF1 764.53 1 0.97 NFE2L1 791.68 0.94 0.82 
AZI2 670.69 0.92 0.90 NONO 1029.18 1 0.96 
B4GALT4 496.83 0.95 0.75 NOP10 529.59 0.97 0.77 
BEX2 381.95 0.90 0.79 NSFL1C 1296.91 0.99 0.96 
BFAR 970.20 1 1 NT5C3 733.05 0.90 0.77 
BIRC3 401.99 1 0.92 NUDT18 680.49 0.95 0.86 
BRD8 982.92 1 1 NUDT2 619.01 1 0.98 
BRF2 896.46 1 0.99 NUDT5 1049.42 1 1 
BRMS1 1006.70 1 1 NUFIP2 580.26 1 0.93 
BSDC1 789.71 1 1 NUP43 874.54 0.95 0.88 
BTK 808.35 1 1 OGFOD1 782.13 1 1 
BTN3A2 573.32 1 0.87 OGFRL1 474.91 0.81 0.75 
C11ORF17 679.51 0.87 0.64 ORMDL1 497.88 0.85 0.79 
C12ORF32 778.41 0.93 0.90 ORMDL3 845.41 0.95 0.89 
C12ORF35 838.63 0.98 0.92 OXR1 484.16 0.75 0.52 
C14ORF102 520.24 0.99 0.88 PACSIN2 565.73 0.87 0.77 
C14ORF129 565.70 1 0.81 PASK 499.80 0.94 0.78 
C14ORF142 589.99 0.93 0.90 PCMTD2 256.23 0.78 0.69 
C14ORF179 795.58 1 0.97 PCNA 558.55 0.86 0.52 
C15ORF63 1278.31 1 1 PDCD2 493.50 0.88 0.66 
C17ORF90 636.12 0.87 0.76 PDCD4 761.35 0.92 0.87 
C18ORF10 468.48 0.79 0.72 PDK3 912.91 0.95 0.92 
C18ORF21 769.53 0.91 0.88 PEA15 754.35 0.73 0.57 
C1ORF123 572.22 0.85 0.70 PEX5 581.60 0.96 0.84 
C1ORF38 1382.12 0.96 0.94 PFDN1 737.82 1 1 
C1ORF85 494.49 0.89 0.65 PFN1 318.03 0.85 0.64 
C1ORF86 959.24 1 1 PHF21A 269.38 0.81 0.64 
C2ORF28 495.29 0.76 0.59 PIGH 583.53 0.97 0.79 
C2ORF44 1093.54 0.99 0.94 PIGN 876.91 0.87 0.85 
C6ORF129 728.78 1 0.93 PIGQ 614.29 0.82 0.73 
C7ORF25 634.51 0.97 0.82 PILRB 455.11 0.79 0.63 
C8ORF40 838.46 0.97 0.92 PIP4K2B 169.65 0.64 0.48 
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C9ORF114 825.45 0.89 0.82 PLAUR 719.26 1 1 
C9ORF78 665.00 0.96 0.87 POLR1D 385.44 0.95 0.74 
CALR 500.59 0.78 0.58 POR 703.65 0.85 0.82 
CAPG 707.90 1 1 PPCS 980.48 0.94 0.93 
CARD8 513.31 1 0.89 PPIL3 1198.30 1 1 
CARD9 775.91 1 1 PRDX5 1004.16 0.95 0.88 
CAT 589.23 1 0.91 PRKAR1A 611.21 0.94 0.86 
CCDC23 873.38 0.96 0.94 PRRC1 868.20 0.96 0.91 
CCDC88B 970.39 0.87 0.81 PTGDR 643.27 0.97 0.88 
CD160 592.79 0.92 0.87 PTGS2 711.44 1 0.80 
CD96 573.27 1 1 PWP1 478.61 0.92 0.86 
CDA 1353.78 1 1 PYGB 968.42 0.90 0.76 
CDAN1 647.05 0.96 0.78 RAB10 1095.53 0.84 0.78 
CDK10 130.28 0.68 0.45 RAB11FIP2 993.41 0.93 0.91 
CEP63 858.12 0.91 0.89 RAB24 763.83 0.90 0.79 
CFDP1 865.78 0.97 0.91 RAB8B 651.53 0.97 0.88 
CHRNB1 849.92 0.93 0.92 RANBP3 519.86 0.84 0.76 
CIB1 777.10 0.76 0.74 RBBP4 633.70 0.87 0.82 
CIDECP 967.82 1 1 RBMX2 550.77 0.91 0.53 
CKS2 700.91 0.94 0.86 RCE1 958.76 0.92 0.77 
CLCN7 582.31 0.83 0.81 RFWD3 553.91 0.95 0.83 
CLN3 716.00 1 0.97 RHOT1 628.72 0.93 0.91 
COBRA1 899.51 0.81 0.65 RNF130 589.05 0.73 0.64 
COMMD4 1013.46 1 1 RNF135 543.23 0.95 0.85 
COMMD7 565.03 0.99 0.71 RNF181 706.38 1 1 
COMMD9 776.21 1 1 RNPS1 412.63 0.70 0.60 
CPPED1 600.82 0.93 0.76 RPA1 559.61 0.89 0.73 
CPSF3L 449.59 0.93 0.76 RPL10A 770.14 0.89 0.86 
CRIPT 518.45 1 0.92 RPL13 852.95 0.95 0.88 
CRISPLD2 1034.78 0.97 0.96 RPL14 671.29 0.99 0.97 
CRLS1 589.05 0.94 0.83 RPL36AL 574.53 0.84 0.74 
CTDSP1 245.44 0.53 0.42 RPL4 722.99 1 1 
CTNNAL1 645.51 0.90 0.82 RPL9 661.41 0.92 0.88 
CTSH 371.70 0.94 0.86 RPP38 794.70 0.96 0.88 
CTSO 608.93 0.98 0.92 RPS6KB2 973.00 0.96 0.89 
CUL4B 817.25 1 1 RPUSD3 916.80 1 1 
CWF19L1 640.57 1 0.93 RPUSD4 1101.65 1 0.99 
CXCL16 899.39 0.88 0.72 RRM2B 677.43 0.93 0.78 
CXCL5 794.46 1 1 RRP12 673.79 1 0.85 
CXXC5 452.06 0.80 0.62 RUFY1 626.22 0.74 0.66 
DCTN5 674.91 0.86 0.78 SAMM50 642.72 0.96 0.93 
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DCXR 324.40 0.75 0.52 SCAND1 496.43 0.87 0.67 
DDOST 1132.84 1 1 SDAD1 1010.52 1 1 
DDX41 828.38 0.96 0.92 SENP2 838.82 0.95 0.92 
DDX52 873.73 1 1 SERPINB8 803.85 0.92 0.87 
DEF6 561.85 1 1 SERTAD1 1102.76 0.84 0.78 
DGUOK 632.13 1 1 SERTAD2 582.79 0.79 0.70 
DHRS1 705.05 0.99 0.88 SESN3 742.60 0.83 0.80 
DHRS3 334.45 0.94 0.78 SETD3 1150.20 0.86 0.83 
DHX29 767.86 0.87 0.79 SF3A1 530.72 0.85 0.75 
DHX38 1022.45 1 1 SF3A3 1036.68 1 0.97 
DIAPH2 518.43 0.96 0.80 SF3B4 948.31 1 1 
DKFZP686I15217 980.48 1 1 SH2D1B 722.32 1 1 
DLAT 623.66 1 0.90 SHCBP1 828.27 0.96 0.94 
DNAJC15 835.13 1 1 SHROOM4 830.56 0.99 0.93 
DNAJC8 375.05 0.98 0.89 SIDT2 895.54 0.87 0.80 
DOCK10 186.84 0.88 0.56 SIRPB1 894.23 1 1 
DOCK11 416.21 0.77 0.53 SIRPG 979.11 1 0.97 
DR1 473.86 0.95 0.76 SLAMF7 434.43 0.96 0.77 
DRAM1 230.57 0.71 0.49 SLC27A3 640.91 0.84 0.65 
DSTYK 883.87 0.91 0.86 SLC35A3 865.36 0.98 0.92 
DUS2L 739.71 0.97 0.81 SLC39A8 433.18 0.95 0.84 
E2F2 460.43 0.84 0.77 SLC3A2 888.93 0.94 0.90 
E2F6 561.66 0.94 0.78 SLC40A1 781.17 0.94 0.92 
EBP 696.64 0.91 0.82 SMAP1 591.71 0.95 0.87 
ECH1 928.06 1 1 SMARCE1 721.27 1 0.95 
ECHS1 195.40 0.59 0.45 SNAP29 507.51 0.93 0.71 
EEF1G 1240.69 1 1 SNORA70 805.53 1 0.96 
EIF1AX 552.87 0.88 0.70 SNRNP25 430.19 0.88 0.71 
EIF2AK4 781.47 0.95 0.90 SNX14 771.09 0.98 0.91 
EIF2B2 1080.54 1 1 SNX29 873.04 1 0.91 
EIF2S3 601.99 0.90 0.73 SP110 963.83 1 0.87 
EIF4A1 542.22 0.97 0.85 SPNS1 731.89 0.98 0.92 
EIF4G3 294.18 0.78 0.57 SRI 532.23 1 0.85 
EIF5 319.81 0.82 0.68 SRP54 614.96 1 1 
EMR3 649.13 1 0.96 STARD3NL 769.57 0.98 0.94 
EPB41 933.50 0.92 0.86 STAT3 637.01 0.96 0.88 
EPHX2 567.37 0.85 0.78 STAT4 720.58 1 0.95 
ERCC3 442.15 0.98 0.78 STAT5A 908.67 0.96 0.88 
ERP27 658.69 1 0.83 STAT6 1238.77 1 1 
ETS2 303.17 0.88 0.73 STOM 691.30 1 0.95 
EVI2A 735.79 0.99 0.85 STYXL1 870.17 0.93 0.81 
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EXOC4 636.98 1 1 SUMF1 561.63 0.98 0.87 
F13A1 899.97 1 0.97 SURF6 585.70 0.97 0.91 
FAM193B 520.18 0.77 0.62 SUSD3 645.17 0.98 0.91 
FAM49A 528.11 0.80 0.73 SYS1 612.65 1 1 
FAM76B 679.80 0.91 0.88 TAF1C 513.54 0.86 0.67 
FAR2 576.17 1 1 TAF1L 396.71 0.81 0.67 
FBXO11 153.56 0.71 0.49 TAGLN 1038.40 1 1 
FCER1G 941.32 1 0.98 TAPBPL 1231.22 1 0.86 
FCRL3 775.73 0.96 0.80 TATDN2 552.59 0.93 0.79 
FDFT1 732.41 0.96 0.89 TBC1D15 1166.57 1 1 
FEZ2 731.32 0.86 0.64 TBC1D2B 794.52 0.94 0.74 
FN3KRP 654.05 0.90 0.82 TCEAL8 850.76 1 1 
FRG1 559.90 0.98 0.89 TDP2 1093.58 0.99 0.96 
FXYD5 660.71 0.91 0.82 TFE3 712.39 0.86 0.80 
GAB3 835.89 0.87 0.83 TFG 464.63 0.96 0.92 
GALC 787.67 0.97 0.95 THAP7 339.32 0.95 0.80 
GAPT 528.83 1 0.77 TLR7 761.71 1 1 
GATAD2A 505.88 0.75 0.63 TMEM140 564.34 1 1 
GATS 119.20 0.65 0.46 TMEM149 858.12 1 0.90 
GDPD3 1063.49 1 0.96 TMEM175 657.46 0.83 0.73 
GMCL1 658.06 0.86 0.81 TMEM199 706.46 0.98 0.94 
GNA12 722.36 0.90 0.80 TNFRSF4 545.47 0.89 0.82 
GNPAT 947.19 1 0.99 TNFSF8 948.24 1 0.89 
GPAA1 556.60 0.71 0.57 TOMM7 1088.64 1 1 
GPATCH4 1133.92 1 1 TPM1 378.53 0.78 0.75 
GPX7 588.48 0.93 0.81 TRAF3IP3 1277.39 1 1 
GRK6 539.47 0.95 0.79 TRAF5 978.67 0.95 0.89 
GSPT2 703.47 1 1 TRAK1 1273.42 1 1 
GTF2F1 420.48 0.95 0.84 TRAPPC4 834.08 1 1 
H1F0 758.59 0.87 0.66 TRAPPC5 701.23 0.90 0.73 
HADH 795.50 0.94 0.85 TRAPPC6B 798.97 1 1 
HARS2 593.39 1 1 TRIM4 546.64 0.98 0.94 
HBP1 499.89 0.75 0.66 TRPC4AP 909.87 0.97 0.92 
HBQ1 648.99 0.65 0.63 TSPAN33 585.97 0.99 0.98 
HCLS1 1193.39 1 1 TSSC1 685.42 1 0.96 
HDDC2 753.18 0.83 0.75 TUBA1A 862.11 0.98 0.95 
HDHD1 781.23 0.89 0.82 TUBA1B 715.79 0.98 0.96 
HEBP2 544.33 0.89 0.78 TUFM 741.53 1 0.95 
HIF1AN 705.80 1 0.88 TXNIP 969.72 1 1 
HIST1H2BD 701.43 1 0.99 UBA7 720.04 1 0.90 
HNRNPC 932.01 1 0.98 UBE2L3 737.06 0.92 0.88 
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HNRNPH3 453.81 0.97 0.82 UBL4A 866.24 0.85 0.83 
HPS1 524.99 0.97 0.85 UBN1 694.43 0.64 0.42 
HSCB 1029.53 1 1 UBR2 870.48 0.98 0.91 
HSD17B11 543.85 1 0.75 UGDH 564.06 0.90 0.83 
HSD17B12 813.02 1 0.99 UQCC 275.76 1 0.59 
HSP90AB1 663.04 0.96 0.91 USO1 683.82 1 0.91 
HSPA4 534.87 0.88 0.82 USP4 652.99 0.97 0.92 
HSPA8 806.84 1 0.96 USP48 764.11 0.90 0.85 
HSPA9 803.88 0.94 0.92 UTP18 423.66 0.87 0.71 
ICOS 687.29 0.94 0.76 UXT 923.69 1 1 
ID3 614.86 1 0.93 VAMP1 429.91 0.90 0.80 
IKBIP 476.12 0.83 0.67 VAMP8 1193.93 1 1 
IL18R1 660.24 1 1 VASP 559.59 0.87 0.81 
IL8 585.82 1 1 VEZT 686.02 0.98 0.96 
ILF3 621.12 0.90 0.78 VIM 553.86 0.87 0.76 
IPP 802.33 0.98 0.78 VPS4B 746.41 1 0.91 
IQCB1 698.57 1 0.89 WAS 1086.37 1 1 
IQGAP1 865.04 0.95 0.89 WDFY2 463.45 0.86 0.67 
ITGAM 849.98 0.98 0.91 WDR45 469.64 0.91 0.68 
ITGAX 959.37 1 0.99 XBP1 515.17 0.87 0.76 
ITK 588.87 1 0.99 XRCC6BP1 667.70 0.98 0.92 
KATNA1 365.26 0.86 0.76 YIF1A 1041.26 0.97 0.95 
KCTD10 917.67 1 0.83 YIPF3 604.21 1 1 
KIAA0319L 400.98 0.70 0.63 ZAK 826.41 0.94 0.83 
KIAA0368 238.50 0.83 0.69 ZDHHC17 949.15 0.93 0.91 
KIAA1191 676.71 1 0.98 ZFP90 633.00 0.88 0.68 
KIAA1598 828.53 0.81 0.67 ZMIZ1 180.24 0.72 0.38 
KIAA1737 601.89 0.83 0.75 ZMIZ2 1107.48 0.91 0.90 
KLF4 378.59 0.80 0.60 ZNF185 1046.58 1 1 
KLHDC4 303.59 0.78 0.64 ZNF266 958.87 1 1 
KRIT1 733.81 0.95 0.93 ZNF407 764.85 1 1 
LACTB 456.72 0.74 0.65 ZNF439 687.04 1 1 
LAPTM5 1147.57 1 1 ZNF549 815.31 1 0.78 
LARP4 948.51 1 1 ZNF613 913.90 1 1 
LASS5 717.42 0.90 0.76 ZNF671 743.34 1 1 
LDLRAP1 598.40 0.93 0.86 ZNF75D 818.75 1 1 
LFNG 749.90 1 0.94 ZNF787 633.16 0.67 0.66 
LILRB2 1260.17 1 0.99 ZNF839 801.56 0.98 0.95 
LINS 545.28 0.96 0.90 ZRANB1 601.90 0.99 0.72 




Table A.2 The number of rare, common, and private SNPs and an estimate of the 


















ABCC5 2 26 11 0.00044 LMAN2L 6 13 7 0.00056 
ABHD10 9 19 11 0.00144 LMNA 2 14 7 0.00044 
ABHD8 5 16 10 0.00165 LONP2 5 23 13 0.00065 
ACAA2 2 17 7 0.00042 LRPPRC 5 45 16 0.00097 
ACADM 11 28 17 0.00214 LRRC25 0 11 5 0.00002 
ACER3 2 10 3 0.00080 LRRCC1 1 24 12 0.00026 
ACOX1 3 18 7 0.00034 LTN1 5 18 12 0.00066 
ACP2 4 11 6 0.00059 M6PR 3 19 9 0.00065 
ACTR10 1 20 12 0.00027 MAD2L1BP 0 15 6 0.00012 
ACTR6 1 25 16 0.00018 MAF1 3 24 11 0.00059 
ADCK3 2 13 6 0.00037 MAGEH1 1 9 5 0.00025 
ADK 2 10 3 0.00072 MAN2A2 4 24 10 0.00089 
ADPGK 1 22 7 0.00037 MAPK1IP1L 3 24 15 0.00081 
ADRM1 0 18 11 0.00011 MAU2 3 16 10 0.00039 
ADSS 1 14 7 0.00029 MBNL1 1 12 10 0.00016 
AHSA2 3 25 15 0.00074 MBNL2 1 11 5 0.00010 
AKR7A3 2 18 10 0.00036 MED16 7 27 21 0.00177 
ALDH16A1 6 26 14 0.00128 MED22 7 21 10 0.00097 
ALDH2 0 8 4 0.00021 MEFV 2 22 13 0.00057 
ALDH3B1 3 35 17 0.00081 MFN2 2 29 17 0.00083 
ALKBH1 4 17 4 0.00044 MGST3 13 26 13 0.00285 
ALPL 2 24 11 0.00031 MKI67IP 1 16 8 0.00023 
ALPP 7 25 11 0.00120 MOBKL2C 5 21 7 0.00061 
ALS2 3 14 9 0.00049 MPHOSPH10 4 18 8 0.00092 
ANXA11 3 12 6 0.00052 MPL 2 18 9 0.00052 
AOAH 8 18 11 0.00191 MR1 2 26 12 0.00043 
AP1G2 0 14 8 0.00003 MRPL17 6 35 15 0.00108 
AP1S1 5 20 12 0.00093 MRPL34 3 13 11 0.00076 
APOL3 5 16 7 0.00109 MRPL43 2 13 6 0.00044 
ARAF 3 13 10 0.00040 MRPL52 5 11 2 0.00089 
ARGLU1 3 18 13 0.00067 MRPL53 1 22 9 0.00029 
ARID5B 3 12 6 0.00047 MRPS21 4 22 12 0.00097 
ARL16 5 16 8 0.00084 MSH6 7 15 12 0.00134 
ARPP19 1 23 8 0.00034 MSI2 1 14 8 0.00048 
ASNSD1 4 24 11 0.00067 MSRA 6 20 14 0.00092 
ASXL2 3 15 8 0.00053 MTMR3 2 14 5 0.00023 
ATG4A 2 5 3 0.00050 MYC 4 20 8 0.00038 
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ATMIN 4 19 12 0.00050 NAA10 3 10 1 0.00050 
ATP13A1 1 25 15 0.00029 NDUFB10 8 24 10 0.00123 
ATP5J2 1 27 9 0.00036 NEDD8 2 17 10 0.00027 
ATP5S 2 24 10 0.00084 NEDD9 3 20 10 0.00041 
ATPIF1 7 19 9 0.00139 NFE2L1 4 14 7 0.00083 
AZI2 2 20 11 0.00054 NONO 0 8 4 0.00002 
B4GALT4 6 15 4 0.00077 NOP10 6 16 4 0.00104 
BEX2 6 9 3 0.00086 NSFL1C 6 19 10 0.00130 
BFAR 1 21 19 0.00007 NT5C3 7 14 6 0.00142 
BIRC3 1 22 11 0.00011 NUDT18 5 17 9 0.00179 
BRD8 3 16 9 0.00071 NUDT2 6 19 10 0.00091 
BRF2 7 19 9 0.00119 NUDT5 2 16 11 0.00025 
BRMS1 0 13 6 0.00003 NUFIP2 1 18 8 0.00016 
BSDC1 0 12 5 0.00004 NUP43 1 13 6 0.00030 
BTK 1 9 5 0.00012 OGFOD1 4 18 8 0.00085 
BTN3A2 9 18 9 0.00119 OGFRL1 5 11 6 0.00068 
C11ORF17 0 16 7 0.00066 ORMDL1 4 30 16 0.00084 
C12ORF32 6 17 7 0.00121 ORMDL3 1 19 7 0.00026 
C12ORF35 4 28 16 0.00078 OXR1 1 12 8 0.00009 
C14ORF102 2 18 10 0.00035 PACSIN2 4 17 4 0.00086 
C14ORF129 3 16 9 0.00045 PASK 4 30 11 0.00115 
C14ORF142 4 15 8 0.00080 PCMTD2 5 10 6 0.00097 
C14ORF179 0 27 18 0.00007 PCNA 3 14 11 0.00026 
C15ORF63 0 23 8 0.00007 PDCD2 5 20 7 0.00094 
C17ORF90 2 14 9 0.00027 PDCD4 4 15 10 0.00045 
C18ORF10 2 12 8 0.00051 PDK3 6 10 5 0.00119 
C18ORF21 3 23 13 0.00065 PEA15 1 10 4 0.00010 
C1ORF123 1 17 11 0.00023 PEX5 3 19 10 0.00080 
C1ORF38 5 17 7 0.00050 PFDN1 2 11 8 0.00044 
C1ORF85 1 15 7 0.00013 PFN1 1 25 14 0.00054 
C1ORF86 4 24 10 0.00091 PHF21A 1 11 2 0.00022 
C2ORF28 3 22 15 0.00046 PIGH 4 30 9 0.00136 
C2ORF44 4 11 5 0.00055 PIGN 3 19 10 0.00033 
C6ORF129 1 17 12 0.00018 PIGQ 1 14 10 0.00029 
C7ORF25 5 12 6 0.00086 PILRB 1 13 6 0.00053 
C8ORF40 1 20 11 0.00056 PIP4K2B 1 16 7 0.00034 
C9ORF114 4 11 4 0.00071 PLAUR 2 15 5 0.00050 
C9ORF78 7 14 8 0.00158 POLR1D 8 30 15 0.00093 
CALR 2 19 8 0.00036 POR 3 14 10 0.00050 
CAPG 3 20 10 0.00055 PPCS 1 18 10 0.00032 
CARD8 18 15 9 0.00351 PPIL3 0 13 6 0.00030 
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CARD9 1 29 20 0.00035 PRDX5 4 28 16 0.00060 
CAT 7 13 4 0.00143 PRKAR1A 1 20 10 0.00025 
CCDC23 3 11 5 0.00072 PRRC1 7 15 7 0.00153 
CCDC88B 6 18 11 0.00110 PTGDR 7 23 12 0.00104 
CD160 2 8 4 0.00020 PTGS2 2 20 9 0.00036 
CD96 9 19 7 0.00190 PWP1 7 16 7 0.00084 
CDA 13 15 6 0.00201 PYGB 5 20 7 0.00119 
CDAN1 4 12 5 0.00070 RAB10 1 19 15 0.00053 
CDK10 5 16 6 0.00121 RAB11FIP2 0 8 5 0.00039 
CEP63 3 23 12 0.00095 RAB24 2 10 6 0.00065 
CFDP1 4 35 20 0.00122 RAB8B 1 25 15 0.00032 
CHRNB1 0 12 10 0.00025 RANBP3 0 6 3 0.00007 
CIB1 5 11 6 0.00150 RBBP4 3 22 11 0.00034 
CIDECP 7 17 14 0.00105 RBMX2 0 14 3 0.00007 
CKS2 9 27 13 0.00104 RCE1 1 10 6 0.00020 
CLCN7 8 12 6 0.00247 RFWD3 8 26 14 0.00166 
CLN3 1 24 14 0.00033 RHOT1 2 20 12 0.00047 
COBRA1 4 18 6 0.00060 RNF130 7 14 7 0.00126 
COMMD4 2 27 14 0.00050 RNF135 0 27 10 0.00081 
COMMD7 1 17 8 0.00020 RNF181 1 16 10 0.00017 
COMMD9 7 15 11 0.00105 RNPS1 2 14 9 0.00088 
CPPED1 4 39 18 0.00096 RPA1 3 20 11 0.00106 
CPSF3L 1 10 5 0.00019 RPL10A 5 27 16 0.00074 
CRIPT 3 34 18 0.00069 RPL13 0 41 18 0.00049 
CRISPLD2 11 21 13 0.00146 RPL14 5 33 15 0.00088 
CRLS1 4 19 11 0.00111 RPL36AL 3 20 8 0.00086 
CTDSP1 4 27 17 0.00063 RPL4 3 26 16 0.00047 
CTNNAL1 2 9 6 0.00086 RPL9 6 27 19 0.00098 
CTSH 8 15 10 0.00161 RPP38 4 36 18 0.00091 
CTSO 13 21 10 0.00203 RPS6KB2 1 11 11 0.00060 
CUL4B 1 8 2 0.00025 RPUSD3 5 24 11 0.00044 
CWF19L1 6 23 15 0.00080 RPUSD4 5 25 14 0.00087 
CXCL16 3 14 6 0.00078 RRM2B 7 22 13 0.00102 
CXCL5 4 17 9 0.00057 RRP12 5 17 9 0.00094 
CXXC5 2 8 3 0.00032 RUFY1 2 27 12 0.00073 
DCTN5 3 23 16 0.00042 SAMM50 2 12 5 0.00039 
DCXR 4 14 5 0.00080 SCAND1 2 15 6 0.00022 
DDOST 2 21 10 0.00035 SDAD1 2 20 9 0.00048 
DDX41 1 17 10 0.00014 SENP2 1 15 8 0.00025 
DDX52 2 22 6 0.00072 SERPINB8 6 23 19 0.00085 
DEF6 2 23 11 0.00055 SERTAD1 3 25 16 0.00062 
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DGUOK 2 17 9 0.00042 SERTAD2 1 16 5 0.00062 
DHRS1 3 18 9 0.00074 SESN3 2 11 2 0.00058 
DHRS3 1 19 11 0.00027 SETD3 2 17 12 0.00055 
DHX29 3 29 15 0.00051 SF3A1 6 10 6 0.00093 
DHX38 4 17 9 0.00088 SF3A3 4 17 9 0.00069 
DIAPH2 4 15 7 0.00031 SF3B4 6 15 9 0.00042 
DKFZP686I15217 2 22 13 0.00037 SH2D1B 3 16 8 0.00078 
DLAT 3 27 12 0.00083 SHCBP1 1 21 9 0.00012 
DNAJC15 11 16 7 0.00225 SHROOM4 1 23 11 0.00034 
DNAJC8 5 16 11 0.00101 SIDT2 1 24 12 0.00021 
DOCK10 3 27 14 0.00100 SIRPB1 4 22 14 0.00083 
DOCK11 2 11 5 0.00015 SIRPG 10 21 12 0.00136 
DR1 5 15 4 0.00084 SLAMF7 0 19 12 0.00004 
DRAM1 9 14 5 0.00128 SLC27A3 3 11 7 0.00033 
DSTYK 3 14 10 0.00062 SLC35A3 3 17 9 0.00051 
DUS2L 2 15 8 0.00021 SLC39A8 1 17 10 0.00018 
E2F2 2 8 7 0.00033 SLC3A2 4 20 12 0.00028 
E2F6 3 22 9 0.00072 SLC40A1 6 13 8 0.00130 
EBP 2 10 5 0.00023 SMAP1 6 16 7 0.00109 
ECH1 4 23 11 0.00056 SMARCE1 1 20 15 0.00025 
ECHS1 1 5 1 0.00045 SNAP29 5 18 7 0.00111 
EEF1G 0 20 14 0.00003 SNORA70 1 10 3 0.00007 
EIF1AX 2 17 12 0.00025 SNRNP25 3 24 12 0.00078 
EIF2AK4 5 27 13 0.00095 SNX14 3 18 9 0.00063 
EIF2B2 2 16 11 0.00053 SNX29 2 11 6 0.00068 
EIF2S3 4 15 9 0.00063 SP110 5 17 10 0.00068 
EIF4A1 5 31 20 0.00083 SPNS1 2 25 11 0.00018 
EIF4G3 1 14 6 0.00040 SRI 4 24 13 0.00070 
EIF5 5 18 10 0.00096 SRP54 8 32 21 0.00163 
EMR3 0 24 13 0.00019 STARD3NL 7 19 9 0.00144 
EPB41 2 14 7 0.00042 STAT3 1 15 9 0.00028 
EPHX2 4 15 3 0.00060 STAT4 4 15 7 0.00063 
ERCC3 0 24 15 0.00007 STAT5A 0 11 6 0.00003 
ERP27 7 25 9 0.00178 STAT6 1 12 4 0.00015 
ETS2 5 11 4 0.00072 STOM 3 23 13 0.00076 
EVI2A 5 16 8 0.00125 STYXL1 5 21 13 0.00157 
EXOC4 0 20 11 0.00045 SUMF1 5 19 10 0.00069 
F13A1 5 29 16 0.00090 SURF6 1 15 10 0.00013 
FAM193B 1 14 7 0.00036 SUSD3 7 16 10 0.00160 
FAM49A 5 11 8 0.00075 SYS1 5 19 10 0.00096 
FAM76B 5 31 19 0.00136 TAF1C 12 31 19 0.00260 
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FAR2 7 14 4 0.00116 TAF1L 1 20 7 0.00022 
FBXO11 2 22 13 0.00038 TAGLN 6 35 14 0.00100 
FCER1G 3 25 20 0.00054 TAPBPL 1 15 4 0.00047 
FCRL3 5 16 7 0.00113 TATDN2 5 21 7 0.00060 
FDFT1 7 51 28 0.00142 TBC1D15 3 9 3 0.00047 
FEZ2 6 25 15 0.00205 TBC1D2B 10 12 6 0.00132 
FN3KRP 2 21 7 0.00044 TCEAL8 1 11 4 0.00024 
FRG1 4 22 10 0.00165 TDP2 4 23 10 0.00064 
FXYD5 4 21 15 0.00068 TFE3 4 9 4 0.00026 
GAB3 0 10 7 0.00001 TFG 4 29 9 0.00106 
GALC 8 19 13 0.00122 THAP7 8 26 11 0.00140 
GAPT 5 32 16 0.00106 TLR7 1 18 8 0.00015 
GATAD2A 2 21 14 0.00046 TMEM140 7 16 12 0.00154 
GATS 0 7 3 0.00019 TMEM149 6 17 11 0.00070 
GDPD3 2 20 11 0.00040 TMEM175 1 10 5 0.00017 
GMCL1 4 22 10 0.00098 TMEM199 1 24 10 0.00014 
GNA12 7 22 16 0.00138 TNFRSF4 4 27 18 0.00046 
GNPAT 5 30 13 0.00121 TNFSF8 5 22 15 0.00141 
GPAA1 0 12 4 0.00025 TOMM7 12 17 5 0.00265 
GPATCH4 0 22 7 0.00052 TPM1 1 14 4 0.00084 
GPX7 4 17 10 0.00106 TRAF3IP3 1 13 10 0.00042 
GRK6 1 11 6 0.00013 TRAF5 1 28 15 0.00025 
GSPT2 2 9 7 0.00033 TRAK1 2 29 18 0.00080 
GTF2F1 1 16 7 0.00048 TRAPPC4 10 30 9 0.00155 
H1F0 1 11 8 0.00023 TRAPPC5 4 17 9 0.00092 
HADH 1 14 7 0.00018 TRAPPC6B 4 19 9 0.00045 
HARS2 3 16 9 0.00061 TRIM4 2 16 15 0.00033 
HBP1 6 21 12 0.00124 TRPC4AP 1 15 7 0.00025 
HBQ1 0 16 6 0.00034 TSPAN33 2 19 12 0.00044 
HCLS1 1 9 5 0.00009 TSSC1 8 20 9 0.00148 
HDDC2 6 17 9 0.00149 TUBA1A 1 18 10 0.00029 
HDHD1 3 13 3 0.00072 TUBA1B 5 27 15 0.00107 
HEBP2 1 20 13 0.00077 TUFM 2 15 8 0.00048 
HIF1AN 6 19 12 0.00107 TXNIP 1 20 13 0.00019 
HIST1H2BD 5 40 21 0.00072 UBA7 0 10 6 0.00002 
HNRNPC 1 19 10 0.00027 UBE2L3 3 19 9 0.00082 
HNRNPH3 0 29 21 0.00026 UBL4A 3 8 3 0.00047 
HPS1 2 21 13 0.00034 UBN1 7 23 13 0.00198 
HSCB 2 18 9 0.00034 UBR2 3 17 13 0.00055 
HSD17B11 5 19 8 0.00096 UGDH 8 21 9 0.00144 
HSD17B12 4 26 12 0.00073 UQCC 2 17 5 0.00054 
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HSP90AB1 12 38 15 0.00199 USO1 4 15 8 0.00056 
HSPA4 3 19 12 0.00062 USP4 1 13 8 0.00023 
HSPA8 15 41 23 0.00139 USP48 4 21 7 0.00066 
HSPA9 0 31 13 0.00017 UTP18 2 27 13 0.00045 
ICOS 6 11 8 0.00068 UXT 0 7 4 0.00002 
ID3 6 42 28 0.00113 VAMP1 11 15 8 0.00201 
IKBIP 2 25 14 0.00043 VAMP8 3 19 7 0.00067 
IL18R1 4 12 9 0.00084 VASP 0 14 4 0.00005 
IL8 3 14 8 0.00081 VEZT 5 15 10 0.00073 
ILF3 4 30 12 0.00109 VIM 1 21 10 0.00050 
IPP 5 21 9 0.00120 VPS4B 0 23 14 0.00010 
IQCB1 2 18 10 0.00036 WAS 0 14 8 0.00008 
IQGAP1 2 17 9 0.00107 WDFY2 0 28 17 0.00007 
ITGAM 2 17 7 0.00056 WDR45 0 10 5 0.00005 
ITGAX 3 20 10 0.00050 XBP1 2 9 7 0.00049 
ITK 2 19 9 0.00028 XRCC6BP1 6 15 10 0.00161 
KATNA1 4 17 6 0.00087 YIF1A 1 12 8 0.00037 
KCTD10 5 13 9 0.00062 YIPF3 2 25 18 0.00033 
KIAA0319L 0 8 6 0.00017 ZAK 0 25 9 0.00099 
KIAA0368 0 17 9 0.00008 ZDHHC17 3 18 7 0.00049 
KIAA1191 4 15 10 0.00059 ZFP90 8 19 8 0.00159 
KIAA1598 0 18 11 0.00013 ZMIZ1 2 17 6 0.00075 
KIAA1737 1 11 3 0.00028 ZMIZ2 0 7 3 0.00031 
KLF4 0 26 16 0.00030 ZNF185 8 14 8 0.00159 
KLHDC4 3 27 13 0.00054 ZNF266 6 21 10 0.00116 
KRIT1 3 17 10 0.00064 ZNF407 5 16 9 0.00070 
LACTB 6 15 8 0.00143 ZNF439 3 32 16 0.00068 
LAPTM5 12 26 22 0.00252 ZNF549 2 25 13 0.00062 
LARP4 0 17 12 0.00003 ZNF613 1 18 8 0.00057 
LASS5 2 22 6 0.00055 ZNF671 1 15 8 0.00029 
LDLRAP1 1 11 5 0.00022 ZNF75D 0 8 6 0.00005 
LFNG 5 32 17 0.00088 ZNF787 0 14 8 0.00019 
LILRB2 5 27 10 0.00092 ZNF839 1 16 7 0.00010 
LINS 7 25 15 0.00128 ZRANB1 3 16 9 0.00058 
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